UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 10-Q

(Mark One) $\hfill \boxtimes$ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2015

OR $\hfill\Box$ Transition report pursuant to Section 13 or 15(d) of the exchange act of 1934

For the transition period from	to	
Commission File Num	aber: 000-33155	
Coale		
COATES INTERNA		
(Exact name of registrant as s	pecified in its charter)	
Delaware	22-2925432	
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)	
2100 Highway 34, Wall Towns (Address of principal executive		
(732) 449-7 (Registrant's telephone numbe		
N/A (Former name, former address and former fis	scal year, if changed since last report)	
Indicate by check mark whether the registrant (1) has filed all reports required to during the preceding 12 months (or for such shorter period that the registrant v requirements for the past 90 days.		
Indicate by check mark whether the registrant has submitted electronically an required to be submitted and posted pursuant to Rule 405 of Regulation S-T (shorter period that the registrant was required to submit and post such files).		
Indicate by check mark whether the registrant is a large accelerated filer, an acce the definitions of "large accelerated filer," "accelerated filer" and "smaller report		orting company. See
Large accelerated filer \square	Accelerated filer Non-accelerated filer \square]
Non-accelerated filer \square (Do not check if a smaller reporting company	Smaller reporting company ⊠	
Indicate by check mark whether the registrant is a shell company (as defined in R	tule 12b-2 of the Exchange Act.)	Yes □ No ⊠
As of August 11, 2015, the Registrant had 951,408,169 shares of its common stoo	ck, par value \$0.0001 per share issued and outstanding	g.

COATES INTERNATIONAL, LTD. AND SUBSIDIARIES QUARTERLY REPORT ON FORM 10-Q

CONTENTS

JUNE 30, 2015

		Page
PART I	I – FINANCIAL INFORMATION	
Item 1.	Financial Statements:	
	Balance Sheets	3
	Statements of Operations	4
	Condensed Statements of Cash Flows	5
	Notes to Financial Statements	6-31
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	32-41
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	42
Item 4.	Controls and Procedures	42
PART I	II – OTHER INFORMATION	
Item 1.	Legal Proceedings	43
Item 1A	. Risk Factors	43
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	43
Item 3.	Defaults Upon Senior Securities	43
Item 4.	Mine Safety Disclosures	43
Item 5.	Other Information	43
Item 6.	Exhibits	44
SIGNA'	TURES	45
	- 2 -	

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

Coates International, Ltd. Balance Sheets

	June 30, 2015 (Unaudited)		De	ecember 31, 2014
Assets	(,	Chaudited)		
Current Assets Cash	\$	107.831	\$	263,526
 	Э	145,583	Э	47,274
Inventory, net Deferred offering costs and other assets		3,348		44,874
Total Current Assets	_		_	
	_	256,762	_	355,674
Property, plant and equipment, net		2,125,402		2,119,010
Deferred licensing costs, net		44,591		46,732
Total Assets	\$	2,426,755	\$	2,521,416
Liabilities and Stockholders' Deficiency				
Current Liabilities				
Accounts payable and accrued liabilities	\$	2,044,479	\$	1,982,777
Promissory notes to related parties		1,501,505		1,565,505
Deferred compensation payable		1,078,524		1,079,904
Derivative liability related to convertible promissory notes		403,800		475,695
Deposits		150,595		19,124
Convertible promissory notes, net of unamortized discount		109,577		500,905
Current portion of license deposits		60,725		517,500
Mortgage loan payable		60,000		1,448,284
Current portion of finance lease obligation, net of unamortized discount		53,191		62,102
Total Current Liabilities	Ξ	5,462,396	Ξ	7,651,796
Non-current portion of mortgage loan payable		1,358,284		-
Non-current portion of license deposits		730,975		283,800
Non-current portion of finance lease obligation, net of unamortized discount		-		19,349
Total Liabilities	_	7.551.655	_	
Total Entonities	_	7,551,655	_	7,954,945
Commitments and Contingencies		-		-
Stockholders' Deficiency				
Preferred stock, \$0.001 par value, 100,000,000 shares authorized:				
Series A Preferred Stock, 1,000,000 shares designated, 50,000 and 50,000 shares issued and outstanding at June				
30, 2015 and December 31, 2014, respectively		50		50
Series B Convertible Preferred Stock, 5,000,000 shares designated, 2,952,487 and 585,502 shares issued and				
outstanding at June 30, 2015 and December 31, 2014, respectively		2,953		586
Common Stock, \$0.0001 par value, 2,000,000,000 shares authorized, 918,416,994 shares issued and outstanding				
at June 30, 2015 and 1,000,000,000 shares authorized, 443,508,090 shares issued and outstanding at December 31,				
2014		91,842		44,351
Additional paid-in capital		48,386,338		41,288,663
Accumulated deficit		(53,606,083)		(46,767,179)
Total Stockholders' Deficiency		(5,124,900)		(5,433,529)
Total Liabilities and Stockholders' Deficiency	\$	2,426,755	\$	2,521,416
·				

The accompanying notes are an integral part of these financial statements.

Coates International, Ltd. Statements of Operations (Unaudited)

	_	For the Three Months Ended June 30,			Months	For the Six Months Ended June 30,		
	_	2015	_	2014	_	2015	_	2014
Sublicensing fee revenue	\$	4,800	\$	4,800	\$	9,600	\$	9,600
Total Revenues		4,800		4,800		9,600		9,600
Expenses:								
Research and development costs		95,833		105,424		189,744		219,594
Compensation and benefits		3,557,777		1,527,224		5,786,012		1,644,809
General and administrative expenses		129,090		176,692		277,294		324,192
Depreciation and amortization		11,797		16,100		27,759		32,721
Total Operating Expenses		3,794,497		1,825,440		6,280,809		2,221,316
Loss from Operations		(3,789,697)		(1,820,640)		(6,271,209)		(2,211,716)
Other Income (Expense):			-					_
Decrease (increase) in estimated fair value of embedded derivative liabilities		27,863		(289,563)		71,895		(172,547)
Loss on conversion of convertible notes		(133,566)		(25,089)		(238,070)		(61,713)
Interest expense, net		(128,735)	_	(218,226)	_	(401,520)	_	(418,761)
Total other income (expense)		(234,438)		(532,878)		(567,695)		(653,021)
Loss Before Income Taxes		(4,024,135)		(2,353,518)		(6,838,904)		(2,864,737)
Provision for income taxes		-		-		-		-
Net Loss	\$	(4,024,135)	\$	(2,353,518)	\$	(6,838,904)	\$	(2,864,737)
			_		_			
Basic net loss per share	\$	(0.01)	\$	(0.01)	\$	(0.01)	\$	(0.01)
Basic weighted average shares outstanding		741,205,172		378,637,252		623,659,033		357,564,038
Diluted net loss per share	\$	(0.01)	\$	(0.01)	\$	(0.01)	\$	(0.01)
Diluted weighted average shares outstanding	_	741,205,172		378,637,252		623,659,033		357,564,038

The accompanying notes are an integral part of these financial statements.

Coates International Ltd. Condensed Statements of Cash Flows (Unaudited)

For the Six

	Months Ended June 30,			ed
		2015	_	2014
Net Cash Used in Operating Activities	\$	(429,364)	\$	(724,908)
Cash Used in Investing Activities	\$	(22,358)	\$	-
Cash Flows Provided by Financing Activities:				
Issuance of convertible promissory notes		252,500		425,500
Issuance of common stock under equity purchase agreements		207,261		161,636
Issuance of promissory notes to related parties		60,000		-
Repayment of promissory notes to related parties		(124,000)		(100,000)
Repayment of convertible promissory notes		(52,750)		-
Repayment of mortgage loan		(30,000)		(35,000)
Finance Lease Obligation Payments		(16,984)		(22,668)
Issuance of common stock and warrants to the son of a director		-		290,000
Net Cash Provided by Financing Activities		296,027		719,468
Net Decrease in Cash		(155,695)		(5,440)
Cash, beginning of period		263,526		49,274
Cash, end of period	\$	107,831	\$	43,834
Supplemental Disclosure of Cash Flow Information:				
Cash paid during the period for interest	\$	59,565	\$	124,259
Supplemental Disclosure of Non-cash Financing Activities:				
Conversion of convertible promissory notes	\$	668,968	\$	138,320
Conversion of Promissory Notes to Related Parties to Common Stock		-		437,186
Conversion of additional paid in capital to Promissory Note to Gregory Coates		-		1,462,093
Stock-based compensation award to George J. Coates for lost benefits or property ownership		-		950,000
	\$	668,968	\$	2,987,599
	_			

The accompanying notes are an integral part of these financial statements.

Coates International, Ltd. Notes to Financial Statements June 30, 2015 (All amounts rounded to thousands of dollars) (Unaudited)

1. THE COMPANY AND BASIS OF PRESENTATION

Nature of Organization

Coates International, Ltd. (the "Company" or "CIL") is a Delaware corporation organized in October 1991 as successor-in-interest to a Delaware corporation of the same name incorporated in August 1988. Coates International, Ltd. operates in Wall Township, New Jersey.

The Company has acquired the exclusive licensing rights for the Coates spherical rotary valve ("CSRV®") system technology in North America, Central America and South America (the "CSRV® License"). The CSRV® system technology has been developed over a period of more than 20 years by the Company's founder George J. Coates, President and Chief Executive Officer, and his son Gregory G. Coates. The CSRV® system technology is adaptable for use in piston-driven internal combustion engines of many types and has been patented in the United States and numerous countries throughout the world.

Management believes that the CSRV engines provide the following advantages as compared to conventional internal combustion engines designed with "poppet valves":

- Improved fuel efficiency
- Lower levels of harmful emissions
- Adaptability to numerous types or engine fuels
- Longer engine life
- Longer intervals between engine services

The CSRV® system technology is designed to replace the intake and exhaust conventional "poppet valves" currently used in almost all piston-driven, automotive, truck, motorcycle, marine and electric power generator engines, among others. Unlike conventional valves which protrude into the engine combustion chamber, the CSRV® system technology utilizes spherical valves that rotate in a cavity formed between a two-piece cylinder head. The CSRV® system technology utilizes significantly fewer moving parts than conventional poppet valve assemblies. As a result of these design improvements, management believes that engines incorporating the CSRV® system technology ("Coates Engines") will last significantly longer and will require less lubrication over the life of the engine, as compared to conventional engines. In addition, CSRV® Engines can be designed with larger openings into the engine cylinder than with conventional valves so that more fuel and air can be inducted into, and expelled from, the cylinder in a shorter period of time. Larger valve openings permit higher revolutions-per-minute (RPM's) and permit higher compression ratios with lower combustion chamber temperatures, allowing the Coates Engine to produce more power than equivalent conventional engines. The extent to which, higher RPM's, greater volumetric efficiency and thermal efficiency can be achieved with the CSRV® system technology, is a function of the engine design and application.

Hydrogen Reactor Technology Owned by George J. Coates

George J. Coates has developed a hydrogen reactor, which rearranges H₂O water molecules into HOH molecules also known as Hydroxy-Gas. The Hydroxy-Gas produced by the hydrogen reactor is then harvested for use as a type of fuel. Mr. Coates intends to continue with development of this technology to enable the harvested Hydroxy-Gas to be utilized as the fuel source to power our patented CSRV® engines. This technology has been successfully applied to a small CSRV® engine which is solely powered by Hydroxy gas produced by the reactor from water. However, at this time, the Hydrogen Reactor technology development has been temporarily deferred to enable the Company to focus on producing a limited number of natural gas powered CSRV® industrial electric power generator sets ("Gen Sets)". The next phase of this research and development will focus on powering larger, industrial engines. If successful, this application will only require a ready supply of water and would be suitable for stationary engines and generators. Conventional internal combustion engines employing poppet valve assemblies require lubrication and would experience excessive heat and friction if powered with Hydroxy-Gas. This, in turn, would cause the engines to burn out in a rather short period of time. The materials and components of the CSRV® engines do not require such lubrication and because of their design, are able to operate relatively troublefree on Hydroxy-Gas as the engine fuel. There can be no assurance that this technology can be developed successfully, or that if developed, it will be feasible to penetrate the internal combustion engine market with this technology. Applications for patent protection of this technology will be filed upon completion of the research and development. Although at this time no arrangements have been made between the Company and George J. Coates, owner of the technology, regarding licensing of the hydrogen reactor, Mr. Coates has provided his commitment to license this technology to the Company once the related patent protection is in place. Accordingly, the Company does not currently have any rights to manufacture, use, sell and distribute the Hydrogen Reactor technology, should it become commercially feasible to manufacture and distribute products powered by the Hydroxy-Gas fuel. The Company has been and continues to be responsible for all costs incurred related to the development of this technology.

Basis of Presentation

The accompanying financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") and rules and regulations of the Securities and Exchange Commission (the "SEC").

Since the Company's inception, the Company has been responsible for the development costs of the CSRV® technology in order to optimize the value of the licensing rights and has incurred related operational costs, the bulk of which have been funded primarily through cash generated from licensing fees, sales of stock, short term convertible promissory notes, capital contributions, loans made by George J. Coates, Gregory G. Coates, Bernadette Coates, his spouse and certain directors, fees received from research and development of prototype models and a small number of CSRV® engine generator sales. The Company has incurred substantial cumulative losses from operations since its inception. Losses from operations are expected to continue until the Coates Engines are successfully introduced into and accepted in the marketplace, or the Company receives substantial licensing revenues. These losses from operations were substantially related to research and development of the Company's intellectual property rights, patent filing and maintenance costs and general and administrative expenses. The Company has also incurred substantial non-cash expenses for stock-based compensation.

As shown in the accompanying financial statements, the Company has incurred recurring losses from operations and, as of June 30, 2015, had a stockholders' deficiency of (\$5,125,000). In addition, the current economic environment, which is characterized by tight credit markets, investor uncertainty about how to safely invest their funds and low investor confidence, has introduced additional risk and difficulty to the Company's challenge to secure needed additional working capital. These factors raise substantial doubt about the Company's ability to continue as a going concern. Management has instituted a cost control program intended to restrict variable costs to only those expenses that are necessary to complete its activities related to entering the production phase of operations, develop additional commercially feasible applications of the CSRV® system technology, seek additional sources of working capital and cover general and administrative costs in support of such activities. The Company has been actively undertaking efforts to secure new sources of working capital. At June 30, 2015, the Company had negative working capital of (\$5,206,000) compared with negative working capital of (\$7,296,000) at the end of 2014.

In the fourth quarter of 2011, the Company identified cracks on the lower engine heads of its Gen Sets that resulted from a defect in the manufacturing by one of its suppliers. Based on testing of the Gen Sets to confirm the Company's resolution of this problem, management believes it has determined the cause of this cracked head condition. The Company has placed orders for new production parts, including sets of engine heads and has also modified certain patterns is in the process of manufacturing a limited number of Gen Sets. Thereafter, it will undertake field testing of the Gen Sets, after which, it intends to begin to ramp-up production.

The Company continues to actively seek out new sources of working capital; however, there can be no assurance that it will be successful in these efforts. The accompanying financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

Certain amounts included in the accompanying financial statements for the three and six months ended June 30, 2014 have been reclassified in order to make them comparable to the amounts presented for the three and six months ended June 30, 2015.

Majority-Owned Subsidiary

CIL is currently the majority shareholder of Coates Hi-Tech Engines, Ltd., a Delaware corporation which was formed in July 2012. It has not commenced operations and has no assets.

Revenue Recognition

Sales and cost of sales are recognized at the time of shipment, provided the risk of loss has transferred to the customer and collection of the sales price is reasonably assured. Shipping arrangements and costs are the responsibility of the customer.

Revenue from research and development activities is recognized when collection of the related revenues is reasonably assured and, when applicable, in accordance with Accounting Standards Update No. 2010-17, "Milestone Method of Revenue Recognition, a consensus of the FASB Emerging Issues Task Force". This standard provides guidance on defining a milestone and permits recognition of revenue from research and development that is contingent upon achievement of one or more specified milestones defined in the research and development arrangements which meet specified criteria for such revenue recognition.

Deposits represent cash deposits received with orders to purchase Gen Sets.

License deposits, which are non-refundable, were received from the granting of sublicenses and are recognized as earned, generally commencing upon the completion of certain tests of the $CSRV^{\otimes}$ products and acceptance by the licensee or upon commencement of production ramp-up activities for orders placed by the sublicensee. At that time, license revenue will be recognized ratably over the period of time that the sublicense has been granted using the straight-line method. Upon termination of a sublicense agreement, non-refundable license deposits, less any costs related to the termination of the sublicense agreement, are recognized as revenue. Revenue from research and development activities is recognized when earned and realization is reasonably assured, provided that financial risk has been transferred from the Company to its customer.

The Company is recognizing the license deposit of \$300,000 on the Canadian License, discussed in Note 5, as revenue on a straight-line basis over the approximate remaining life through 2027 of the last $CSRV^{\otimes}$ technology patent in force.

Research and Development

Research and development costs are expensed when incurred. Included in accounts payable and accrued liabilities at June 30, 2015 and 2014 is \$115,000 for the estimated remediation costs of previously sold Gen Sets that were determined to have cracked heads.

Intellectual Property

Under a licensing agreement with George J. Coates and Gregory G. Coates, the Company obtained the rights to manufacture, use and sell the CSRV[®] engine technology throughout the territory defined as the Western Hemisphere. In accordance with GAAP, the Company is not permitted to record a value for this intellectual property because it was obtained from principal stockholders, and, accordingly, this intangible asset is not reflected in the accompanying financial statements.

Licensing Costs

Under the $CSRV^{\otimes}$ Licensing Agreement for the $CSRV^{\otimes}$ engine technology, the Company is responsible for all costs in connection with applying for and maintaining patents to protect the $CSRV^{\otimes}$ system technology. Such costs are expensed as incurred.

Stock-Based Compensation

Stock-based compensation expense, which does not require any outlay of cash, consists of the following:

- The estimated fair value of shares of the Company's capital stock issued to key employees for anti-dilution protection pursuant to a resolution of the board of directors. This includes restricted shares of Series A Preferred Stock and Series B Convertible Preferred Stock. In 2014, the Company arranged for an independent professional services firm to determine the estimated fair value of Series A Preferred Stock issued in August 2014 and Series B Preferred Stock issued in July 2014. The approach to arriving at the estimated fair value of the Series B Convertible Preferred Stock was determined to have a close correlation to the trading price of the Company's common stock. Accordingly, upon each subsequent issuance of shares of Series B Convertible Preferred Stock, the original estimated fair value determined by the independent valuation is adjusted, on a pro rata basis, to reflect the closing price of the Company's common stock on each date of issuance.
- Compensation expense relating to stock options and stock awards under its stock option and incentive plans is recognized as an expense
 using the fair value measurement method. Under the fair value method, the estimated fair value of awards to employees is charged to
 income on a straight-line basis over the requisite service period, which is the earlier of the employee's retirement eligibility date or the
 vesting period of the award.

Deferred Compensation

Deferred compensation represents compensation of George J. Coates and Bernadette Coates earned, but not paid, in order to preserve the Company's working capital. The Company intends to repay these amounts at such time that it has sufficient working capital and after the related party notes to George J. Coates and Bernadette Coates have been repaid with interest thereon.

Inventory

Inventory consists of raw materials and work-in-process, including overhead and is stated at the lower of cost or market determined by the first-in, first-out method. Inventory items designated as obsolete or slow moving are reduced to net realizable value. Market value is determined using current replacement cost.

Property, Plant and Equipment

Property, plant and equipment is stated at cost. Depreciation is computed using the straight-line method over the estimated useful life of the assets: 40 years for buildings and building improvements, 3 to 7 years for machinery and equipment and 5 to 10 years for furniture and fixtures. Repairs and maintenance expenditures, which do not extend the useful lives of the related assets, are expensed as incurred.

In the event that facts and circumstances indicate that long-lived assets may be impaired, an evaluation of recoverability is performed. In the event that such evaluation indicates that there has been an impairment of one or more long-lived assets, the cost basis of such assets would be adjusted accordingly at that time.

Income Taxes

Deferred income tax assets and liabilities are computed for differences between the financial statement and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future. Such deferred income tax asset and liability computations are based on enacted tax laws and rates applicable to periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized and are adjusted when conditions indicate that deferred assets will be realized. Income tax expense (benefit) is the tax payable or refundable for the period, plus or minus the change during the period in deferred tax assets and liabilities.

The Company evaluates any uncertain tax positions for recognition by determining if the weight of available evidence indicates it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes. In the event recognition of an uncertain tax position is indicated, the Company measures the tax benefit as the largest amount which is more than 50% likely of being realized upon ultimate settlement. This process of evaluating and estimating uncertain tax positions and tax benefits requires the consideration of many factors, which may require periodic adjustments and which may not accurately forecast actual outcomes. Interest and penalties, if any, related to tax contingencies would be included in income tax expense.

Loss per Share

Basic net loss per share is based on the weighted average number of common shares outstanding without consideration of potentially dilutive shares of common stock. There were no shares of preferred stock outstanding with rights to share in the Company's net income during the three and six months ended June 30, 2015 and 2014. Diluted net income per share is based on the weighted average number of common and potentially dilutive common shares outstanding, when applicable.

Use of Estimates

The preparation of the Company's financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. These significant estimates include determining the fair value of convertible promissory notes containing embedded derivatives and variable conversion rates, determining a value for shares of Series A Preferred Stock and Series B Convertible Preferred Stock issued, assigning useful lives to the Company's property, plant and equipment, determining an appropriate amount to reserve for obsolete and slow moving inventory, estimating a valuation allowance for deferred tax assets, assigning expected lives to, and estimating the rate of forfeitures of, stock options granted and selecting a trading price volatility factor for the Company's common stock in order to estimate the fair value of the Company's stock options on the date of grant or other appropriate measurement date. Actual results could differ from those estimates.

2. CONCENTRATIONS OF CREDIT AND BUSINESS RISK

The Company maintains cash balances with two financial institutions. Monies on deposit with one of the institutions is currently fully insured by the Federal Deposit Insurance Corporation. Monies on deposit at the other financial institution amounting to \$3,000 are invested in a fund that invests in securities with maturities of 60 days or less.

The Company's operations are devoted to the development, application and marketing of the CSRV® system technology which was invented by George J. Coates, the Company's founder, Chairman, Chief Executive Officer, President and controlling stockholder. Development efforts have been conducted continuously during this time. From July 1982 through May 1993, seven U.S. patents as well as a number of foreign patents were issued with respect to the CSRV® system technology. Since inception of the Company in 1988, all aspects of the business have been completely dependent upon the activities of George J. Coates. The loss of George J. Coates' availability or service due to death, incapacity or otherwise would have a material adverse effect on the Company's business and operations. The Company does not presently have any key-man life insurance in force for Mr. Coates.

3. FAIR VALUE OF FINANCIAL INSTRUMENTS

Cash, Other Assets, Accounts Payable and Accrued Liabilities and Other Liabilities

With the exception of convertible promissory notes, the carrying amount of these items approximates their fair value because of the short term maturity of these instruments. The convertible promissory notes are reported at their estimated fair value, determined as described in more detail in Note 14.

Limitations

Fair value estimates are made at a specific point in time, based on relevant market information and information about the financial instrument. These estimates are subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. Changes in assumptions could significantly affect the estimates.

4. LICENSING AGREEMENT AND DEFERRED LICENSING COSTS

The Company holds a manufacturing, use, lease and sale license from George J. Coates and Gregory G. Coates for the $CSRV^{\otimes}$ system technology in the territory defined as the Western Hemisphere (the "License Agreement"). Under the License Agreement, George J. Coates and Gregory G. Coates granted to the Company an exclusive, perpetual, royalty-free, fully paid-up license to the intellectual property that specifically relates to an internal combustion engine that incorporates the $CSRV^{\otimes}$ system technology (the " $CSRV^{\otimes}$ Engine") and that is currently owned or controlled by them (the " $CSRV^{\otimes}$ Intellectual Property"), plus any $CSRV^{\otimes}$ Intellectual Property that is developed by them during their employment with the Company. In the event of insolvency or bankruptcy of the Company, the licensed rights would terminate and ownership would revert back to George J. Coates and Gregory G. Coates.

Under the License Agreement, George J. Coates and Gregory G. Coates agreed that they will not grant any Western Hemisphere licenses to any other party with respect to the CSRV[®] Intellectual Property.

At June 30, 2015 and December 31, 2014, deferred licensing costs, comprised of expenditures for patent costs incurred pursuant to the $CSRV^{\textcircled{0}}$ licensing agreement, net of accumulated amortization, amounted to \$45,000 and \$47,000, respectively. Amortization expense for the three months ended June 30, 2015 and 2014 amounted to \$1,000 and \$1,000, respectively. Amortization expense for the six months ended June 30, 2015 and 2014 amounted to \$2,000 and \$2,000, respectively.

5. AGREEMENTS ASSIGNED TO ALMONT ENERGY, INC.

Almont Energy Inc. ("Almont"), a privately held, independent third-party entity based in Alberta, Canada is the assignee of a sublicense which provides for a \$5,000,000 license fee to be paid to the Company and covers the use of the CSRV® system technology in the territory of Canada in the oil and gas industry (the "Canadian License"). Almont is also the assignee of a separate research and development agreement ("R&D Agreement") which requires that Almont pay the remaining balance of an additional \$5,000,000 fee to the Company in consideration for the development and delivery of certain prototype engines. The Company completed development of the prototypes in accordance with this agreement at the end of 2007. The R&D Agreement has not been reduced to the form of a signed, written agreement.

Almont is also the assignee of an escrow agreement (the "Escrow Agreement") that provides conditional rights to a second sublicense agreement from the Company for the territory of the United States (the "US License"). The US License has been deposited into an escrow account and the grant of the license will not become effective until the conditions for release from escrow are satisfied. The US License provides for a license fee of \$50 million.

The Escrow Agreement requires that Almont, as the assignee, make a payment ("Release Payment") to the Company equal to the then remaining unpaid balance of the Canadian License licensing fee, the R&D Agreement fee and the down payment of \$1,000,000 required under the US License. It is not likely that Almont will be able to make additional payments of the Release Payment until the Company can raise sufficient new working capital to commence production and shipment of Gen Sets to Almont. At June 30, 2015, the remaining balance of the Release Payment due to the Company was \$5,847,000.

6. NON-EXCLUSIVE DISTRIBUTION SUBLICENSE WITH RENOWN POWER DEVELOPMENT, LTD.

In February 2015, the Company granted a non-exclusive distribution sublicense to Renown Power Development, Ltd., a China-based sales and distribution company ("Renown") covering the territory defined as the Western Hemisphere. Under this sublicense, Renown will be permitted to sell, lease and distribute CSRV® products. This sublicense provides for payment of licensing fees amounting to US\$100 million. The Company received an initial non-refundable deposit of \$500,000 to date. In addition, after Renown receives an aggregate of US\$10,000,000, it is required to pay the Company 25% of all funds it receives from any and all sources until the entire US\$100 million licensing fee is paid in full. In the event that Renown completes one or more capital raises aggregating US\$300 million or more, the remaining unpaid balance of the US\$100 million licensing fee shall become immediately due and payable.

As collateral for payment of the sublicensing fee, Coates Power, Ltd. an independent China-based manufacturing company that will produce CSRV® products in China ("Coates Power") and Renown are to place shares of their capital stock representing a 25% ownership interest into an escrow account for the benefit of the Company. These shares of stock will be released from escrow and revert back to Coates Power and Renown only after the US\$100 million sublicensing fee is paid in full. The Company does not have an ownership interest in Coates Power or Renown. Coates Power and Renown are controlled and managed by Mr. James Pang, the Company's liaison agent in China.

Coates Power has agreed to initially source it production parts and components from the Company. In February 2015, the Company received an order from Coates Power for approximately US\$131,000 of production parts and components, at cost, in connection with its plans to manufacture two initial Gen Sets. In June, 2015, by mutual consent of the parties, it was agreed that the Company would assemble two completed Gen Sets for shipment to Coates Power in China in lieu of shipping the parts and components. This amount is included in Deposits in the accompanying balance sheet at June 30, 2015.

7. INVENTORY

Inventory consisted of the following:

		June 30, 2015	De	cember 31, 2014
Raw materials	\$	478,000	\$	381,000
Work-in-process	·	55,000	•	53,000
Less: Reserve for obsolescence		(387,000)		(387,000)
Total	\$	146,000	\$	47,000

8. LICENSE DEPOSITS

License deposits consist of monies received as deposits on sublicense agreements from Renown in the amount of \$498,000 and from Almont in the amount of \$300,000. These deposits are to be recognized as income on a straight-line basis over the remaining period until expiration of the last remaining CSRV® patent in force in 2027. The Company expects that sublicense-related activities by Renown may commence during 2015 and that it will begin recognizing revenue at that time. Recognition of revenue from the Almont license is included in the statements of operations for the six months ended June 30, 2015 and 2014. The current portion of the license deposits represents the portion of the license deposits expected to be recognized as revenue within one year from the balance sheet date. The balance of the license deposits is included in non-current license deposits.

Sublicensing fee revenue for the three months ended June 30, 2015 and 2014 amounted to \$5,000 and \$5,000, respectively. Sublicensing fee revenue for the six months ended June 30, 2015 and 2014 amounted to \$10,000 and \$10,000, respectively.

9. PROPERTY, PLANT AND EQUIPMENT

Property, plant and equipment at cost, less accumulated depreciation, consist of the following:

	June 30,	December 31,
	2015	2014
Land	\$ 1,235,000	\$ 1,235,000
Building	964,000	964,000
Building improvements	83,000	83,000
Machinery and equipment	689,000	658,000
Furniture and fixtures	39,000	39,000
	3,010,000	2,979,000
Less: Accumulated depreciation	(885,000)	(860,000)
Total	\$ 2,125,000	\$ 2,119,000

Depreciation expense amounted to \$11,000 and \$15,000 for the three months ended June 30, 2015 and 2014, respectively. Depreciation expense amounted to \$26,000 and \$31,000 for the six months ended June 30, 2015 and 2014, respectively.

10. MORTGAGE LOAN PAYABLE

The Company has a mortgage loan on the land and building that serves as its headquarters and research and development facility which bears interest at the rate of 7.5% per annum and which, after securing a three year extension from the lender in July 2015, matures in July 2018. Interest expense for the three months ended June 30, 2015 and 2014 on this mortgage amounted to \$27,000 and \$28,000, respectively. Interest expense for the six months ended June 30, 2015 and 2014 on this mortgage amounted to \$45,000 and \$56,000, respectively. The loan requires monthly payments of interest, plus \$5,000 which is being applied to the principal balance. The remaining principal balance at June 30, 2015 was \$1,418,000. The mortgage loan may be prepaid in whole, or, in part, at any time without penalty.

The loan is collateralized by a security interest in all of the Company's assets, the pledge of five million shares of common stock of the Company owned by George J. Coates, which were deposited into escrow for the benefit of the lender and the personal guarantee of George J. Coates. The Company is not permitted to create or permit any secondary mortgage or similar liens on the property or improvements thereon without prior consent of the lender.

11. FINANCE LEASE OBLIGATION

In August 2013, the Company entered into a sale/leaseback financing arrangement with Paradigm Commercial Capital Group Corp ("Paradigm") pursuant to which it sold its research and development and manufacturing equipment in consideration for net cash proceeds of \$133,000. These cash proceeds were net of a deposit on the lease of \$15,000 and transaction costs of \$5,000. Under this arrangement, the Company is leasing back the equipment over a 30-month period, which includes an optional 6-month extension period which will become effective on August 15, 2015. The fixed recurring monthly lease payment amount is \$8,000. The effective interest rate on this lease is 36.6%.

In accordance with generally accepted accounting principles, this sale/leaseback is required to be accounted for as a financing lease. Under this accounting method, the equipment and accumulated depreciation remains on the Company's books and records as if the Company still owned the equipment. This accounting treatment is in accordance with ASC 840-40-25-4, Accounting for Sale-Leaseback Transactions. In addition, the discounted present value of the lease payments is recorded as a lease finance obligation. The difference between the gross sales price for the equipment and the net proceeds received amounted to \$20,000, which has been recorded as unamortized discount on finance lease obligation. This amount is being amortized to interest expense using the interest method over the term of the lease. The finance lease obligation is secured by all of the equipment included in the sale/leaseback transaction and the personal guaranty of George J. Coates.

For the three months ended June 30, 2015 and 2014, interest expense on this lease amounted to \$9,000 and \$13,000, respectively. For the six months ended June 30, 2015 and 2014, interest expense on this lease amounted to \$19,000 and \$28,000, respectively. These amounts are included in interest expense in the accompanying statements of operations.

12. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

Accounts payable and accrued liabilities are as follows:

	June 30,	De	ecember 31,
	 2015		2014
Legal and professional fees	\$ 1,344,000	\$	1,290,000
Accrued interest expense	376,000		374,000
General and administrative expenses	209,000		194,000
Research and development costs	115,000		115,000
Accrued compensation and benefits	 <u>-</u> _		10,000
Total	\$ 2,044,000	\$	1,983,000

13. PROMISSORY NOTES TO RELATED PARTIES

Promissory Notes Issued to George J. Coates

During the six months ended June 30, 2015, the Company issued, in a series of transactions, promissory notes to George J. Coates and received cash proceeds of \$60,000. During the six months ended June 30, 2015 and 2014 the Company repaid promissory notes to George J. Coates in the aggregate principal amount of \$103,000 and \$60,000, respectively. The promissory notes are payable on demand and provide for interest at the rate of 17% per annum, compounded monthly.

On April 28, 2014, pursuant to a board resolution, \$950,000 of additional paid-in capital was converted into a non-interest bearing promissory note due to George J. Coates. Initially, this conversion was characterized as repayment to Mr. Coates of cash outlays from his own personal funds to acquire the Company's headquarters, research and development and warehouse facility. Mr. Coates contributed this property to the Company and did not receive any consideration for this contribution.

On April 29, 2014, Mr. Coates and the Company mutually agreed to convert this \$950,000 promissory note together with \$50,000 principal amount of 17% promissory notes due to Mr. Coates into shares of common stock of the Company at the closing price per share of \$0.0252 per share on April 29, 2014. As a result, 39,682,540 shares of common stock were issued to Mr. Coates.

After due consideration, on May 13, 2014, pursuant to a board resolution and the mutual agreement of the Company and Mr. Coates, the treatment of this transaction was revised to reflect it as a payment due to Mr. Coates to cover his losses in relation to the transfer of title to the headquarters, research and development and warehouse facility to the Company. The Company has also agreed to be responsible for any of Mr. Coates' incremental personal income taxes attributable to this transaction. As a result of this transaction, the Company recorded stock-based compensation expense of \$1,425,000, which includes the estimated liability for Mr. Coates' income taxes. Although the estimated lost benefits of ownership to Mr. Coates exceeded the value of the award, including the income taxes to be paid by the Company, the parties mutually agreed not to increase the award amount and Mr. Coates did not request that any interest be paid to him. The net effect on the Company's balance sheet of this stock-based common stock award and the conversion of \$50,000 principal amount of 17% promissory notes due to Mr. Coates was to increase current liabilities by \$425,000 and increase the stockholders' deficiency by \$425,000.

In addition, during May 2014, by mutual consent between Mr. Coates and the Company, the remaining \$370,000 principal amount of the promissory notes due to Mr. Coates was converted into restricted shares of common stock of the Company at the closing price per share of \$0.029 on May 30, 2014. These promissory notes arose from cash lent to the Company for working capital purposes from Mr. Coates' personal funds. Accordingly, the Company issued 12,749,162 shares of restricted common stock to Mr. Coates. In September 2014, by mutual consent between Mr. Coates and the Company, a \$200,000 portion of the transaction converting promissory notes to common stock was rescinded. Accordingly, 6,896,552 shares of common stock were returned, cancelled and restored to authorized, unissued status and \$200,000 of promissory notes due to Mr. Coates was reinstated as a liability. The net result of this transaction and the partial rescission of this transaction was to reduce current liabilities by \$170,000 and reduce stockholders' deficiency by the same amount.

Promissory Note Issued to Gregory G. Coates

During the period from August 21, 1995 to February 14, 1996, Gregory G. Coates, son of George J. Coates, President, Technology Division and Director, in a series of payments, made cash outlays from his own personal funds on behalf of the Company in an amount which aggregated \$1,462,000 to provide needed working capital to the Company in order for it to continue its operations. Gregory G. Coates contributed these funds to the Company and did not receive any consideration for this contribution. At that time, the \$1,462,000 of cash outlays was added to the Company's additional paid-in capital. Gregory G. Coates has been anticipating that these monies would be repaid to him at such time that the Company had sufficient working capital for this purpose. Gregory G. Coates has requested that this amount of additional paid-in capital be converted into a non-interest bearing promissory note. On April 28, 2014, the board of directors adopted a resolution to convert \$1,462,000 of additional paid-in capital of the Company into a non-interest bearing promissory note payable on demand, due to Gregory G. Coates. As a result, the Company's additional paid-in capital decreased by \$1,462,000 and current liabilities increased by \$1,462,000.

During the six months ended June 30, 2015, the Company repaid promissory notes to Gregory G. Coates in the aggregate principal amount of \$5,000.

Promissory Notes Issued to Bernadette Coates

During the six months ended June 30, 2015 and 2014, the Company repaid promissory notes to Bernadette Coates, spouse of George J. Coates, in the aggregate principal amount of \$16,000 and \$40,000, respectively. The promissory notes are payable on demand and provided for interest at the rate of 17% per annum, compounded monthly.

10% Promissory Note Due to Michael J. Suchar

In June 2014, a 10% promissory note with a balance of \$17,000, due to Michael J. Suchar, director was converted, by mutual consent, into 612,664 restricted shares of common stock at a price per shares of \$0.0285, the closing price of Company's common stock on the date of conversion.

For the three months ended June 30, 2015 and 2014, aggregate interest expense on all promissory notes to related parties amounted to \$19,000 and \$27,000, respectively. For the six months ended June 30, 2015 and 2014, aggregate interest expense on all promissory notes to related parties amounted to \$40,000 and \$67,000, respectively. Unpaid accrued interest on these promissory notes amounting to \$382,000 is included in accounts payable and accrued liabilities in the accompanying balance sheet at June 30, 2015.

14. CONVERTIBLE PROMISSORY NOTES AND EMBEDDED DERIVATIVE LIABILITY

From time to time, the Company issues convertible promissory notes. At June 30, 2015, there were \$235,000 principal amount of convertible promissory notes outstanding. The net proceeds from these convertible notes are used for general working capital purposes. During the six months ended June 30, 2015 and 2014, \$260,000 and \$425,000, respectively, of convertible promissory notes were issued. The notes may be converted into unregistered shares of the Company's common stock at a discount ranging from 30% to 40% of the defined trading price of the common stock on the date of conversion. The defined trading prices are based on the trading price of the stock during a defined period ranging from ten to twenty-five trading days immediately preceding the date of conversion. The conversion rate discount establishes a beneficial conversion feature ("BCF") or unamortized discount, which is required to be valued and accreted to interest expense over the six-month period until the conversion of the notes into restricted shares of common stock is permitted. In addition, the conversion formula meets the conditions that require accounting for convertible notes as derivative liability instruments.

All of the convertible notes become convertible, in whole, or in part, beginning on the six month anniversary of the issuance date and may be prepaid at the option of the Company, generally with a prepayment penalty of from 25% to 50% of the principal amount of the convertible note at any time prior to becoming eligible for conversion.

One convertible promissory note with a balance of \$79,000 is convertible in monthly installments. The Company may elect, at its option to repay each monthly installment in whole, or in part, in cash without penalty. The amount of each installment not paid in cash is converted into shares of the Company's common stock. This convertible note also requires that the conversion price be re-measured 23 trading days after the conversion shares are originally delivered. If the re-measured conversion price is lower, then the Company is required to issue additional conversion shares to the noteholder.

In accordance with GAAP, the estimated fair value of the embedded derivative liability related to the convertible notes is required to be remeasured at each balance sheet date. The estimated fair value of the embedded derivative liabilities related to promissory notes outstanding was measured as the aggregate estimated fair value, based on Level 2 inputs, which included the average of the quoted daily yield curve rates on six-month and one-year treasury securities and the calculated 12-month historical volatility rate on the Company's common stock, when available.

The embedded derivative liability arises because, based on historical trading patterns of the Company's stock, the formula for determining the Conversion Rate is expected to result in a different Conversion Rate than the closing price of the stock on the actual date of conversion (hereinafter referred to as the "Variable Conversion Rate Differential"). The estimated fair values of the derivative liabilities have been calculated based on a Black-Scholes option pricing model.

The following table presents the details of the convertible promissory notes outstanding at June 30, 2015 and December 31, 2014, including the balance of the unamortized discount and the amount of the embedded derivative liability, where applicable:

					Conversion Price Discount				
					from				bedded
	Principal	Amount	Nominal	Effective	Defined	Unamortize	ed Discount	Derivati	ive Liability
	June 30,	December 31,	Interest	Interest	Trading	June 30,	December 31,	June 30,	December 31,
Date Issued	2015	2014	Rate	Rate ⁽¹⁾	Price	2015	2014	2015	2014
6/18/15	\$ 78,000	\$ -	8.00%	112%	39.0% \$	60,000	N/A	\$ 90,000	N/A
5/4/2015	50,000	-	8.00%	215%	35.0%	38,000	N/A	156,000	N/A
4/27/15	28,000	-	12.00%	158%	40.0%	23,000	N/A	105,000	N/A
4/10/15	53,000	-	9.75%	30%	30.0%	4,000	N/A	35,000	N/A
3/23/15	26,000	-	9.75%	152%	30.0%	-	N/A	18,000	N/A
12/16/14	-	28,000	12.00%	55%	40.0%	-	\$ 8,000	-	\$ 31,000
12/5/14	-	53,000	8.00%	160%	39.0%	-	42,000	-	20,000
11/25/14	-	52,000	9.75%	91%	30.0%	-	24,000	-	41,000
11/14/14	-	40,000	8.00%	139%	32.5%	-	30,000	-	54,000
10/2/14	-	40,000	8.00%	113%	35.0%	-	16,000	-	43,000
9/29/14	-	53,000	8.00%	118%	39.0%	-	29,000	-	20,000
9/3/14	-	39,000	12.00%	139%	40.0%	-	15,000	-	38,000
8/29/14	-	53,000	8.00%	105%	39.0%	-	13,000	-	17,000
8/8/14	-	52,000	9.75%	72%	30.0%	-	5,000	-	41,000
7/28/14	-	30,000	12.00%	156%	30.0%	-	6,000	-	25,000
7/9/14	-	83,000	8.00%	120%	39.0%	-	5,000	-	15,000
7/8/14	-	50,000	5.00%	106%	37.0%	-	2,000	-	31,000
6/12/14	-	47,000	8.00%	147%	40.0%	-	-	-	46,000
4/16/14	-	25,000	12.00%	147%	30.0%	-	-	-	17,000
4/16/14	-	24,000	12.00%	175%	40.0%	-	-	-	15,000
4/2/14	=	27,000	9.75%	71%	30.0%	-			22,000
	\$ 235,000	\$ 696,000			\$	125,000	\$ 195,000	\$404,000	\$ 476,000

⁽¹⁾ The effective interest rate reflects the rate required to fully amortize the unamortized discount over the six-month period until the Notes become convertible.

In a series of transactions, during the six months ended June 30, 2015, convertible promissory notes with an aggregate principal balance of \$710,000, including accrued interest thereon were converted into 434,908,904 unregistered shares of common stock. The Company incurred a loss on these conversions amounting to \$238,000 for the six months ended June 30, 2015. In two transactions, during the six months ended June 30, 2015, the Company also repaid \$55,000 of a convertible promissory note, including accrued interest thereon without penalty.

In a series of transactions, during the six months ended June 30, 2014, convertible promissory notes with an aggregate principal balance of \$271,000, including accrued interest thereon were converted into 13,450,299 unregistered shares of common stock. The Company incurred a loss on these conversions amounting to \$62,000 for the six months ended June 30, 2014.

Other income (expense) resulting from the decrease in the estimated fair value of the embedded derivative liabilities amounted to \$28,000 and (\$290,000) for the three months ended June 30, 2015 and 2014, respectively. Other income (expense) resulting from the decrease in the estimated fair value of the embedded derivative liabilities amounted to \$72,000 and (\$173,000) for the six months ended June 30, 2015 and 2014, respectively. These amounts are included in the accompanying statements of operations as decrease (increase) in estimated fair value of embedded derivative liabilities. Interest expense resulting from accretion of the unamortized discount for the three months ended June 30, 2015 and 2014 amounted to \$67,000 and \$138,000, respectively. Interest expense resulting from accretion of the unamortized discount for the six months ended June 30, 2015 and 2014 amounted to \$277,000 and \$249,000, respectively.

At June 30, 2015, the Company had reserved 350,000,000 shares of its unissued common stock for conversion of convertible promissory notes.

The Company made the private placement of these securities in reliance upon Section 4(2) of the Securities Act of 1933, as amended (the "Act"), Rule 506 of Regulation D, and the rules and regulations promulgated thereunder, and/or upon any other exemption from the registration requirements of the Act, as applicable.

15. CAPITAL STOCK

Common Stock

The Company's common stock is traded on OTC Pink Sheets. Investors can find stock quotes and market information for the Company at www.otcmarkets.com market system under the ticker symbol COTE. Effective May 29, 2015, the Company amended its Certificate of Incorporation to increase the number of authorized shares of common stock, par value, \$0.0001 per share (the "Common Stock") to 2,000,000,000. The Company intends to increase the number of authorized shares of common stock in the future on a timely basis, at any point that it is anticipated that issuances of common stock from sales of common stock or conversions of convertible instruments into common stock will warrant such an increase.

The following common stock transactions occurred during the six months ended June 30, 2015:

- In a series of transactions during the six months ended June 30, 2015, convertible promissory notes with an aggregate principal balance of \$710,000, including accrued interest thereon were converted into 434,908,904 unregistered shares of common stock.
- In a series of transactions during the six months ended June 30, 2015, the Company also repaid \$55,000 of convertible promissory notes, including accrued interest thereon without penalty.
- In a series of transactions during the six months ended June 30, 2015, the Company issued 40,000,000 registered shares of its common stock to Southridge Partners II LP under an equity purchase agreement in consideration for \$207,000. The proceeds were used for general working capital.

The following common stock transactions occurred during the six months ended June 30, 2014:

- In a series of transactions during the six months ended June 30, 2014, the Company made private sales, pursuant to stock purchase agreements of 7,339,286 unregistered shares of its common stock and 7,339,286 common stock warrants to purchase one share of its common stock at exercise prices ranging from \$0.035 to of \$0.04 per share in consideration for \$290,000 received from the son of Richard W. Evans, a director. The proceeds were used for general working capital.
- In a series of transactions during the six months ended June 30, 2014, the Company issued 4,403,403 registered shares of its common stock to Dutchess Opportunity Fund II, LP under an equity line of credit in consideration for \$162,000. The proceeds were used for general working capital.
- In a series of transactions during the six months ended June 30, 2014, convertible promissory notes with an aggregate principal balance of \$271,000, including accrued interest thereon were converted into 13,450,299 unregistered shares of common stock.
- A non-interest bearing promissory note due to George J. Coates in the principal amount of \$950,000 was converted, by mutual consent, into
 37,698,413 restricted shares of common stock at an average price per share of \$0.0252 which was equal to the closing price of the Company's
 common stock on the date of conversion.
- In two transactions during the six months ended June 30, 2014, by mutual consent between Mr. Coates and the Company, \$420,000 principal amount of 17% promissory notes due to George J. Coates was converted into 14,733,289 restricted shares of common stock of the Company at the Company's common stock on the respective dates of conversion. These promissory notes arose from cash lent to the Company for working capital purposes from Mr. Coates' personal funds. In September 2014, by mutual consent between Mr. Coates and the Company, a \$200,000 portion of the transaction converting promissory notes to common stock was rescinded. Accordingly, 6,896,552 shares of common stock were returned, cancelled and restored to authorized, unissued status and \$200,000 of promissory notes due to Mr. Coates was reinstated as a liability.

At June 30, 2015, the Company had reserved 397,844,911 shares of its common stock to cover the potential conversion of convertible securities and exercise of stock options and warrants.

Preferred Stock and anti-dilution rights

The Company is authorized to issue 100,000,000 shares of preferred stock, par value, \$0.001 per share (the "Preferred Stock"). The Company may issue any class of the Preferred Stock in any series. The board is authorized to establish and designate series, and to fix the number of shares included in each such series and the relative rights, preferences and limitations as between series, provided that, if the stated dividends and amounts payable on liquidation are not paid in full, the shares of all series of the same class shall share ratably in the payment of dividends including accumulations, if any, in accordance with the sums which would be payable on such shares if all dividends were declared and paid in full, and in any distribution of assets other than by way of dividends in accordance with the sums which would be payable on such distribution if all sums payable were discharged in full. Shares of each such series when issued shall be designated to distinguish the shares of each series from shares of all other series.

There are two series of Preferred Stock that have been designated to date from the total 100,000,000 authorized shares of Preferred Stock. These are as follows:

• Series A Preferred Stock, par value \$0.001 per share ("Series A"), 1,000,000 shares designated, 50,000 and 50,000 shares issued and outstanding as of June 30, 2015 and December 31, 2014, respectively. Shares of Series A entitle the holder to 10,000 votes per share on all matters brought before the shareholders for a vote. These shares are not entitled to receive dividends or share in distributions of capital and have no liquidation preference. All outstanding shares of Series A are owned by George. J. Coates.

In order to enable the Company to raise needed working capital, an anti-dilution arrangement was established which authorized the issuance of shares of Series A to George J. Coates to restore the Coates Family's voting percentage upon any future issuance of new shares of the Company's common stock as a result of a sale or conversion of securities into common stock, provided, however, that no anti-dilution protection shall be available in connection with public offerings of the Company's securities.

During the six months ended June 30, 2014, 38,428 shares of Series A with an estimated fair value of \$96,000 were granted and issued to George J. Coates pursuant to this anti-dilution agreement. On July 3, 2014 all of the 181,664 shares of Series A previously issued to George J. Coates were converted into shares of Series B Convertible Preferred Stock, \$0.001 par value per share ("Series B"), as more fully explained below. All such converted shares of Series A were cancelled and restored to authorized, unissued status. At the same time, the aforementioned anti-dilution protection for Mr. Coates, pursuant to which shares of Series A may be issued, was cancelled and replaced with a new anti-dilution protection arrangement which involves the issuance of shares of Series B as more fully explained below. In August 2014, 50,000 shares of Series A were issued to George J. Coates as an inducement to him to consider offers from investors interested in acquiring substantial ownership interests in the Company, as a means of raising substantial new working capital for the Company. At June 30, 2015, Mr. Coates held all 50,000 shares of Series B he holds.

Total non-cash, stock-based compensation expense from the grant of shares of Series A to Mr. Coates for six months ended June 30, 2014, amounted to \$96,000. This amount is included in stock-based compensation expense in the accompanying statements of operations for six months ended June 30, 2014.

Series B Convertible Preferred Stock, par value \$0.001 per share, 5,000,000 shares designated, 2,952,487 and 585,502 shares issued and outstanding as of June 30, 2015 and December 31, 2014, respectively. Shares of Series B do not earn any dividends and may be converted at the option of the holder at any time beginning on the second annual anniversary date after the date of issuance into 1,000 unregistered shares of the Company's common stock. Holders of Series B are entitled to one thousand votes per share held on all matters brought before the shareholders for a vote.

In the event that either (i) the Company enters into an underwriting agreement for a secondary public offering of securities, or (ii) a change in control of the Company is consummated representing 50% more of the then outstanding shares of Company's common stock, plus the number of shares of common stock into which any convertible preferred stock is convertible, regardless of whether or not such shares are otherwise eligible for conversion, then the Series B may be immediately converted at the option of the holder into restricted shares of the Company's common stock.

In July 2014, the board of directors consented to a modified anti-dilution plan (the "Modified Plan") for George J. Coates.

Under the Modified Plan, for each new share of common stock issued by the Company to non-Coates family members in the future, additional shares of Series B will be issued to Mr. Coates equal to that number of shares of Series B required to maintain his ownership percentage of outstanding shares of common stock outstanding on a pro forma basis, at 78%. The ownership percentage of 78% represents the percentage of outstanding common stock that Mr. Coates originally held at December 31, 2002.

These anti-dilution provisions do not apply to new shares of common stock issued in connection with exercises of employee stock options, a secondary public offering of the Company's securities or a merger or acquisition.

In July 2014, the board of directors consented to an anti-dilution program which provides that shares of Series B be issued to Gregory G. Coates whenever new shares of common stock are issued to non-Coates family members in order to maintain his ownership percentage of common stock at 5.31% of the pro forma number of shares of common stock outstanding, assuming all shares of Series B were converted to common stock. This was his percentage ownership of common stock at December 31, 2002.

In July 2014, the board of directors consented to an anti-dilution program which provides that shares of Series B be issued to Barry C. Kaye whenever new shares of common stock are issued to non-Coates family members in order to maintain his ownership percentage of common stock at 0.04157% of the proforma number of shares of common stock outstanding, assuming all shares of Series B were converted to common stock. This was the weighted average percentage ownership of common stock he purchased, based on the number of shares of common stock outstanding on each date he acquired additional shares of common stock.

The number of shares of Series B outstanding at June 30, 2015, consisted of 2,747,048, 190,711 and 14,728 shares held by George J. Coates, Gregory G. Coates and Barry C. Kaye, respectively. None of the outstanding shares of Series B may be converted prior to July 2, 2016.

For the six months ended June 30, 2015, 2,205,115, 150,118 and 11,752 shares of Series B were issued to George J. Coates, Gregory G. Coates and Barry C. Kaye, respectively, having an estimated fair value of \$5,392,000, \$367,000 and \$29,000, respectively. These amounts were included in stock-based compensation expense in the accompanying statement of operations for the six months ended June 30, 2015.

In the event that all of the 2,952,487 shares of Series B outstanding were converted, once the conversion restrictions lapse, an additional 2,952,487,000 new unregistered shares of common stock would be issued. On a pro forma basis, based on the number of shares of common stock outstanding at June 30, 2015, this would dilute the ownership percentage of non-affiliated stockholders from 69.1% to 16.2%.

To the extent that additional shares of Series B are issued under the anti-dilution plan, the non-affiliated stockholders' percentage ownership of the Company would be further diluted.

16. DEPOSITS

Deposits consisted of the following:

- A deposit received with an order for two CSRV[®] Gen Sets during the six months ended June 30, 2015, from Coates Power, Ltd., a China-based unaffiliated manufacturing company in the amount of \$132,000.
- A \$19,000 non-refundable deposit at June 30, 2015 and December 31, 2014, received from Almont in connection with its order for a Gen Set.

17. SUBLICENSING FEE REVENUE

Sublicensing fee revenue for the three months ended June 30, 2015 and 2014 amounted to \$5,000 and \$5,000, respectively. Sublicensing fee revenue for the six months ended June 30, 2015 and 2014 amounted to \$10,000 and \$10,000, respectively. The Company is recognizing the license deposit of \$300,000 on the Canadian Licensee as revenue on a straight-line basis over the approximate remaining life until 2027 of the last CSRV® technology patent in force.

18. COMPENSATION AND BENEFITS

Compensation and benefits for the six months ended June 30, 2015 and 2014 amounted to \$5,786,000 and \$1,645,000, respectively. This was comprised of non-cash, stock-based compensation expense of \$5,633,000 and \$1,526,000 for the six months ended June 30, 2015 and 2014, respectively. The increase in 2015 primarily resulted from charging to expense, the estimated fair value of shares of Series B Convertible Preferred Stock issued to key executives for anti-dilution. The other component of employee compensation and benefits was for salaries, wages and employee benefits, which amounted to \$153,000 and \$118,000 for the six months ended June 30, 2015 and 2014, respectively. The increase during the six months ended June 30, 2015 primarily resulted because a higher amount compensation and benefits was allocated to research and development expenses during the six months ended June 30, 2014.

19. INCOME (LOSS) PER SHARE

At June 30, 2015, the Company had 197,288,293 shares of common stock potentially issuable upon assumed conversion of:

Description	Number of Underlying Shares of Common Stock	Exercise Price	Number Vested	Number Non- Vested
Description	703.000	\$ 0.02800	703.000	vesteu
Common stock options	100,000	0.02800	100,000	-
Common stock options	,			-
Common stock options	5,607,000	0.06000 0.24000	5,607,000	-
Common stock options	1,800,000		1,800,000	-
Common stock options	2,000,000	0.25000 0.39000	2,000,000	-
Common stock options	50,000 360,000	0.40000	50,000 360,000	-
Common stock options	100.000	0.40000	100,000	-
Common stock options	1,750,000	0.43000	,	-
Common stock options	30,000	1.00000	1,750,000 30,000	-
Common stock options Common stock warrants	1,250,000	0.02000	1,250,000	-
Common stock warrants Common stock warrants	666,667	0.02000	1,230,000 N/A	N/A
Common stock warrants Common stock warrants	2,127,660	0.02230	N/A N/A	N/A N/A
Common stock warrants	5,000,000	0.02500	N/A N/A	N/A N/A
		0.02875	N/A N/A	N/A N/A
Common stock warrants Common stock warrants	1,739,130 333,333	0.03000	N/A N/A	N/A N/A
Common stock warrants	2,714,287	0.03500	N/A N/A	N/A N/A
Common stock warrants	7,125,000	0.04000	N/A N/A	N/A N/A
Common stock warrants	333,333	0.04500	N/A N/A	N/A N/A
Common stock warrants	400,000	0.05000	N/A N/A	N/A N/A
Common stock warrants	2,181,819	0.05500	N/A N/A	N/A N/A
Common stock warrants	171,428	0.05700	N/A	N/A N/A
Common stock warrants	285,714	0.05810	N/A N/A	N/A
Common stock warrants	428,571	0.05850	N/A	N/A
Common stock warrants	2,000,000	0.06000	N/A	N/A
Common stock warrants	4,269,838	0.06250	N/A	N/A
Common stock warrants	333,333	0.06750	N/A	N/A
Common stock warrants	571,429	0.07000	N/A	N/A
Common stock warrants	666,666	0.07000	N/A	N/A
Common stock warrants	416,667	0.12000	N/A	N/A
Common stock warrants	1,200,000	0.25000	N/A	N/A
Common stock warrants	833,333	0.27000	N/A	N/A
Common stock warrants	153,846	0.32500	N/A	N/A
Common stock warrants	142,857	0.35000	N/A	N/A
Convertible promissory notes	149,443,382	(1)	N/A	N/A
Total		(1)	1 N / P 1	1 V / P 1
Total	197,288,293			

⁽¹⁾ The principal amount of convertible promissory notes outstanding at June 30, 2015 was \$235,000. Under the convertible terms of these notes, the number of shares of common stock into which these notes are convertible is variable because the conversion rates of the notes are based on the trading prices of the common stock over a defined number of trading days leading up to the conversion date during a defined conversion rate pricing period. The actual number of shares underlying these convertible instruments will likely vary from the number assumed above. The number of shares underlying these convertible notes was determined based on the defined conversion rates of the various convertible notes, assuming conversion had occurred as of June 30, 2015.

At June 30, 2014, the Company had 63,428,259 shares of common stock potentially issuable upon assumed conversion of convertible securities and exercise of stock options and warrants.

For the six months ended June 30, 2015 and 2014, none of the potentially issuable shares of common stock were assumed to be converted because the Company incurred a net loss in those periods and the effect of including them in the calculation would have been anti-dilutive.

20. STOCK OPTIONS

The Company's 2006 Stock Option and Incentive Plan (the "Stock Plan") was adopted by the Company's board in October 2006. In September 2007, the Stock Plan, by consent of George J. Coates, majority shareholder, was adopted by our shareholders. The Stock Plan provides for the grant of stock-based awards to employees, officers and directors of, and consultants or advisors to, the Company and its subsidiaries, if any. Under the Stock Plan, the Company may grant options that are intended to qualify as incentive stock options within the meaning of Section 422 of the Internal Revenue Code of 1986, as amended ("ISO's"), options not intended to qualify as incentive stock options ("non-statutory options"), restricted stock and other stock-based awards. ISO's may be granted only to employees of the Company. At June 30, 2015, all of the shares of common stock authorized under the Stock Plan had been granted and no further grants may be awarded thereunder.

The Company established a 2014 Stock Option and Incentive Plan (the "2014 Stock Plan") which was adopted by the Company's board on May 30, 2014. On March 2, 2015, the 2014 Stock Plan, by consent of George J. Coates, majority shareholder, was adopted by our shareholders. The 2014 Stock Plan provides for the grant of stock-based awards to employees, officers and directors of, and consultants or advisors to, the Company and its subsidiaries, if any. Under the 2014 Stock Plan, the Company may grant ISO's, non-statutory options, restricted stock and other stock-based awards. ISO's may be granted only to employees of the Company. A total of 50,000,000 shares of common stock may be issued upon the exercise of options or other awards granted under the 2014 Stock Plan. The maximum number of shares with respect to which awards may be granted during any one year to any employee under the 2014 Stock Plan shall not exceed 25% of the 50,000,000 shares of common stock covered by the 2014 Stock Plan. At June 30, 2015, none of the shares of common stock authorized under the 2014 Stock Plan had been granted as stock options or awarded.

The Stock Plan and the 2014 Stock Plan (the "Stock Plans") are administered by the board and the Compensation Committee. Subject to the provisions of the Stock Plans, the board and the Compensation Committee each has the authority to select the persons to whom awards are granted and determine the terms of each award, including the number of shares of common stock subject to the award. Payment of the exercise price of an award may be made in cash, in a "cashless exercise" through a broker, or if the applicable stock option agreement permits, shares of common stock, or by any other method approved by the board or Compensation Committee. Unless otherwise permitted by the Company, awards are not assignable or transferable except by will or the laws of descent and distribution.

Upon the consummation of an acquisition of the business of the Company, by merger or otherwise, the board shall, as to outstanding awards (on the same basis or on different bases as the board shall specify), make appropriate provision for the continuation of such awards by the Company or the assumption of such awards by the surviving or acquiring entity and by substituting on an equitable basis for the shares then subject to such awards either (a) the consideration payable with respect to the outstanding shares of common stock in connection with the acquisition, (b) shares of stock of the surviving or acquiring corporation, or (c) such other securities or other consideration as the board deems appropriate, the fair market value of which (as determined by the board in its sole discretion) shall not materially differ from the fair market value of the shares of common stock subject to such awards immediately preceding the acquisition. In addition to, or in lieu of the foregoing, with respect to outstanding stock options, the board may, on the same basis or on different bases as the board shall specify, upon written notice to the affected optionees, provide that one or more options then outstanding must be exercised, in whole or in part, within a specified number of days of the date of such notice, at the end of which period such options shall terminate, or provide that one or more options then outstanding, in whole or in part, shall be terminated in exchange for a cash payment equal to the excess of the fair market value (as determined by the board in its sole discretion) for the shares subject to such stock options over the exercise price thereof. Unless otherwise determined by the board (on the same basis or on different bases as the board shall specify), any repurchase rights or other rights of the Company that relate to a stock option or other award pursuant to these provisions. The Company may hold in escrow all or any portion of any such consideration in order to effectuate any continuing restrictions.

The board may at any time provide that any stock options shall become immediately exercisable in full or in part, that any restricted stock awards shall be free of some or all restrictions, or that any other stock-based awards may become exercisable in full or in part or free of some or all restrictions or conditions, or otherwise realizable in full or in part, as the case may be.

The board or Compensation Committee may, in its sole discretion, amend, modify or terminate any award granted or made under the Stock Plan, so long as such amendment, modification or termination would not materially and adversely affect the participant.

During the six months ended June 30, 2015, no stock options were granted and 703,000 stock options with an exercise price of \$0.028 per share became vested. During the six months ended June 30, 2014, 703,000 stock options with an exercise price of \$0.028 per share were granted and no stock options became vested. There were no unvested stock options outstanding at June 30, 2015.

During the three months ended June 30, 2015 and 2014, the Company recorded non-cash stock-based compensation expense related to employee stock options amounting to \$2,000 and \$4,000, respectively. During the six months ended June 30, 2015 and 2014, the Company recorded non-cash stock-based compensation expense related to employee stock options amounting to \$7,000 and \$5,000, respectively. At June 30, 2015, all stock-based compensation expense related to non-vested stock options had been fully recognized.

Details of the stock options outstanding under the Company's Stock Option Plan are as follows:

						Weighted
			Weighted			Average Fair
			Average		Weighted	Value Per Stock
	Exercise Price Per	Number	Remaining	Number	Average	Option at Date
	Share	Outstanding	Contractual Life	Exercisable	Exercise Price	of Grant
Balance, 6/30/15	\$0.028 -\$1.000	12,500,000	12	12,500,000	\$0.184	\$0.169

No stock options were exercised, forfeited or expired during the six months ended June 30, 2015 and 2014.

The weighted average fair value of the Company's stock options was estimated using the Black-Scholes option pricing model which requires highly subjective assumptions including the expected stock price volatility. These assumptions were as follows:

Historical stock price volatility	139% - 325%
Risk-free interest rate	0.21%-4.64%
Expected life (in years)	4
Dividend yield	0.00
·	

The valuation assumptions were determined as follows:

- Historical stock price volatility: The Company utilized the volatility in the trading of its common stock computed for the 12 months of trading immediately preceding the date of grant, where available and 175% volatility rate when not available.
- Risk-free interest rate: The Company bases the risk-free interest rate on the interest rate payable on U.S. Treasury securities in effect at the time
 of the grant for a period that is commensurate with the assumed expected option life.
- Expected life: The expected life of the options represents the period of time options are expected to be outstanding. The Company has very limited historical data on which to base this estimate. Accordingly, the Company estimated the expected life based on its assumption that the executives will be subject to frequent blackout periods during the time that the stock options will be exercisable and based on the Company's expectation that it will complete its research and development phase and commence its initial production phase. The vesting period of these options was also considered in the determination of the expected life of each stock option grant.
- No expected dividends.

21. EQUITY PURCHASE AND REGISTRATION RIGHTS AGREEMENTS

Southridge Partners II LP

In July 2014, the Company entered into a 3-year equity purchase agreement (the "EP Agreement") with Southridge Partners II LP, a Delaware limited partnership ("Southridge"). Pursuant to the terms of the EP Agreement, Southridge committed to purchase up to 40,000,000 shares of the Company's common stock, in exchange for consideration not to exceed Ten Million (\$10,000,000) Dollars. The purchase price for the shares of common stock shall be equal to 94% of the lowest closing price of the common stock during the ten trading days that comprise the defined pricing period. The Company is entitled to exercise a Put to Southridge by delivering a Put Notice, which requires Southridge to remit the dollar amount stated in the Put Notice at the end of the pricing period, provided, however, that for each day during the pricing period, if any, that the daily closing price of the Company's common stock is (i) 25% or more below the Floor Price, as defined, or (ii) below the Floor Price, if any, stipulated in the Put Notice issued by the Company, then the dollar amount of the Put shall be reduced by 10% for each such day. The Company may stipulate a Floor Price below which, no shares of common stock may be sold by Southridge, however, the Floor price shall not be lower than the lowest daily volume weighted average price of the common stock during the ten trading days preceding the date of the Put Notice.

The Company also entered into a registration rights agreement (the "Registration Rights Agreement") with Southridge. Pursuant to the terms of the Registration Rights Agreement, in August 2014, the Company filed a registration statement with the SEC covering 40,000,000 shares of common stock underlying the EP Agreement, which was declared effective in September 2014.

During the six months ended June 30, 2015, the Company sold all of the 40,000,000 registered shares of common stock to Southridge and received proceeds of \$207,000, thereby resulting in the termination of this EP Agreement.

Dutchess Opportunity Fund II, LP

In 2011, the Company entered into an investment agreement (the "Investment Agreement") with Dutchess Opportunity Fund II, LP, a Delaware limited partnership ("Dutchess"). Pursuant to the terms of the Investment Agreement, Dutchess committed to purchase, in a series of purchase transactions ("Puts") registered shares of the Company's common stock. The Investment Agreement automatically terminated in August 2014.

The purchase price paid by Dutchess for the registered shares of common stock delivered with each Put was equal to ninety-four percent (94%) of the lowest daily VWAP of the common stock during the five-day trading period beginning on the effective date of the Put.

During the six months ended June 30, 2014, the Company sold 4,403,403 registered shares of its common stock under this equity line of credit with Dutchess and received proceeds of \$162,000, which were used for general working capital purposes. There were no offering costs related to the sales of these shares.

22. INCOME TAXES

Deferred income taxes are determined using the liability method for the temporary differences between the financial reporting basis and income tax basis of the Company's assets and liabilities. Deferred income taxes are measured based on the tax rates expected to be in effect when the temporary differences are included in the Company's tax return. Deferred tax assets and liabilities are recognized based on anticipated future tax consequences attributable to differences between financial statement carrying amounts of assets and liabilities and their respective tax bases.

Deferred tax assets increased by \$1,849,000 and \$863,000 for the three months ended June 30, 2015 and 2014, respectively. Deferred tax assets increased by \$2,884,000 and \$922,000 for the six months ended June 30, 2015 and 2014, respectively. These amounts were fully offset by a corresponding increase in the tax valuation allowance resulting in no net change in deferred tax assets, respectively, during these periods.

No liability for unrecognized tax benefits was required to be reported at June 30, 2015 and 2014. Based on the Company's evaluation, it has concluded that there are no significant uncertain tax positions requiring recognition in the Company's financial statements. The Company's evaluation was performed for tax years ended 2012 through 2014, the only periods subject to examination. The Company believes that its income tax positions and deductions will be sustained on audit and does not anticipate that adjustments, if any, will result in a material change to its financial position. For the six months ended June 30, 2015 and 2014, there were no penalties or interest related to the Company's income tax returns.

At June 30, 2015, the Company had available, \$19,074,000 of net operating loss carryforwards which may be used to reduce future federal taxable income, expiring between 2018 and 2035 and \$8,706,000 of net operating loss carryforwards which may be used to reduce future state taxable income, expiring between 2015 and 2035.

23. RELATED PARTY TRANSACTIONS

Issuances of Common Stock and Warrants

For the six months ended June 30, 2014, issuances of common stock and common stock warrants to related parties are discussed in detail in Note 15.

Issuances and Repayments of Promissory Notes to Related Parties

Issuances and repayments of promissory notes to related parties during the six months ended June 30, 2015 and 2014, are discussed in detail in Note 13. The promissory notes to related parties are payable on demand and provide for interest at the rate of 17% per annum, compounded monthly. At June 30, 2015, interest accrued but not paid on outstanding promissory notes to related parties, aggregated \$382,000.

Issuances of Preferred Stock

Shares of Series B Convertible Preferred Stock awarded to George J. Coates, Gregory G. Coates and Barry C. Kaye during the six months ended June 30, 2015 is discussed in detail in Note 15.

Personal Guaranty and Stock Pledge

In connection with the Company's mortgage loan, George J. Coates has pledged certain of his shares of common stock of the Company to the extent required by the lender and provided a personal guaranty as additional collateral for a mortgage loan on the Company's headquarters facility.

In connection with the Company's sale/leaseback of its research and development and manufacturing equipment, George J. Coates provided his personal guaranty.

Compensation and Benefits Paid

The approximate amount of compensation and benefits, all of which were approved by the board, paid to George J. Coates, Gregory G. Coates and Bernadette Coates, exclusive of stock-based compensation for unregistered, restricted shares of Preferred Stock awarded to George J. Coates and Gregory G. Coates and non-cash, stock-based compensation for employee stock options granted to Gregory G. Coates is summarized as follows:

	roi tile six			
	Months Ended			
	June 30,			
	2015		2014	
George J. Coates (a) (b) (c)	8,000	\$	8,000	
Gregory G. Coates (d)	87,000		87,000	
Bernadette Coates (e)	3,000		2,000	

- (a) For the six months ended June 30, 2015 and 2014, George J. Coates earned additional base compensation of \$125,000 and \$125,000, respectively, payment of which is being deferred until the Company has sufficient working capital. These amounts are included in deferred compensation in the accompanying balance sheets at June 30, 2015 and 2014.
- (b) During the six months ended June 30, 2015, George J. Coates was awarded 2,202,115 shares of Series B Convertible Preferred Stock with an estimated fair value of \$5,393,000 for anti-dilution. Each share of Series B Convertible Preferred Stock becomes convertible into 1,000 shares of common stock at any time after the second anniversary after the date of issuance.
- (c) During the six months ended June 30, 2014, 38,428 shares of Series A Preferred Stock, having an estimated fair value of \$96,000, were granted and issued to George J. Coates pursuant to an anti-dilution agreement.
- (d) During the six months ended June 30, 2015, Gregory G. Coates was awarded 150,118 shares of Series B Convertible Preferred Stock with an estimated fair value of \$367,000 for anti-dilution. Each share of Series B Convertible Preferred Stock becomes convertible into 1,000 shares of common stock at any time after the second anniversary after the date of issuance.
- (e) For the six months ended June 30, 2015 and 2014, Bernadette Coates earned additional base compensation of \$34,000 and \$34,000, respectively, payment of which is being deferred until the Company has sufficient working capital. These amounts are included in deferred compensation in the accompanying balance sheets at June 30, 2015 and 2014.

During the six months ended June 30, 2015 and 2014, Barry C. Kaye, Treasurer and Chief Financial Officer was paid compensation of \$38,000 and \$90,000, respectively. For the three months ended June 30, 2015 and 2014, Mr. Kaye earned compensation of \$27,000 and \$42,000, respectively, which was not paid and is being deferred until the Company has sufficient working capital to remit payment to him. For the six months ended June 30, 2015 and 2014, Mr. Kaye earned compensation of \$62,000 and \$72,000, respectively, which was not paid and is being deferred until the Company has sufficient working capital to remit payment to him. At June 30, 2015, the total amount of Mr. Kaye's unpaid, deferred compensation was \$102,000. This amount is included in accounts payable and accrued liabilities in the accompanying balance sheet at June 30, 2015. During the six months ended June 30, 2015, Barry C. Kaye was awarded 11,752 shares of Series B Convertible Preferred Stock with an estimated fair value of \$29,000 for anti-dilution. Each share of Series B Convertible Preferred Stock becomes convertible into 1,000 shares of common stock at any time after the second anniversary after the date of issuance.

24. CONTRACTUAL OBLIGATIONS AND COMMITMENTS

The following table summarizes our contractual obligations and commitments at June 30, 2015:

	_	Total		2015		2016		2017		2018
Promissory notes to related parties	\$	1,502,000	\$	1,502,000	\$	-	\$	_	\$	-
Mortgage loan payable		1,418,000		30,000		60,000		60,000		1,268,000
Deferred compensation		1,079,000		1,079,000		-		-		-
Convertible promissory notes		234,000		79,000		155,000		-		-
Finance lease obligation		61,000		61,000		-		-		-
Total	\$	4,294,000	\$	2,751,000	\$	215,000	\$	60,000	\$	1,268,000

25. LITIGATION AND CONTINGENCIES

The Company is not a party to any litigation that is material to its business.

26. RECENTLY ISSUED ACCOUNTING STANDARDS

In July 2015, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update No. 2014-15, "Inventory – Simplifying the Measurement of Inventory (Topic 330)". This update requires that inventory value be measured at the lower of cost or net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. Currently, generally accepted accounting principles require that inventory be valued at the lower of cost or market price to replace the inventory. This update is to become effective for annual and interim financial statements for fiscal years ending after December 15, 2016. Earlier application is permitted. This update is required to be applied prospectively. The Company is currently evaluating the impact of this update; however, at this time it does not expect it will have a material effect on its financial statements.

In August 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update No. 2014-15, "Presentation of Financial Statements - Going Concern (Subtopic 205-40)", which was issued in order to provide guidance about management's responsibility to evaluate whether there is substantial doubt about an entity's ability to continue as a going concern and to provide related financial statement disclosures. It requires that management evaluate whether there are conditions or events, when considered in the aggregate, that raise substantial doubt about the entity's ability to continue as a going concern within one year after the date of both the annual and interim financial statements ("Going Concern Doubt"). The evaluation should be based on relevant conditions and events that are known and reasonably knowable at the date of the financial statements. When such evaluation determines that Going Concern Doubt does exist, then management is required to consider whether or not it is probable that its plans to mitigate the Going Concern Doubt can be effective and timely to address the Going Concern Doubt. This update also provides disclosure requirements in the notes to financial statements both when such doubt is probable of being mitigated and when such doubt is not probable of being mitigated by management's plans. This update is to become effective for annual and interim financial statements for fiscal years ending after December 15, 2016. As permitted thereunder, the Company has elected to implement this update early and it has been applied in the financial statements for the six months ended June 30, 2015. Early adoption did not have a material effect on the Company's financial position or results of operations.

In May 2014, the FASB issued Accounting Standards Update No. 2014-09, "Revenue from Contracts with Customers," (Topic 606): which amended the existing accounting standards for revenue recognition. The amendments are based on the principle that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The Company will be required to adopt this accounting standard in the first quarter of fiscal 2018. Early adoption is not permitted. The amendments may be applied retrospectively to each prior period presented or retrospectively with the cumulative effect recognized as of the date of initial application. The Company is currently evaluating the impact of these amendments and the transition alternatives; however, at this time it does not anticipate that it will have a material effect on its financial statements.

27. SUBSEQUENT EVENTS

Equity Purchase and Registration Rights Agreements

On July 29, 2015, the Company entered into a new 3-year equity purchase agreement (the "2015 EP Agreement") with Southridge Partners II LP, a Delaware limited partnership ("Southridge"). Pursuant to the terms of the 2015 EP Agreement, Southridge committed to purchase up to 205,000,000 shares of the Company's common stock, in exchange for consideration not to exceed Twenty Million (\$20,000,000) Dollars. The purchase price for the shares of common stock shall be equal to 94% of the lowest closing price of the common stock during the ten trading days that comprise the defined pricing period. The Company is entitled to exercise a Put to Southridge by delivering a Put Notice, which requires Southridge to remit the dollar amount stated in the Put Notice at the end of the pricing period, provided, however, that for each day during the pricing period, if any, that the daily closing price of the Company's common stock is (i) 25% or more below the Floor Price, as defined, or (ii) below the Floor Price, if any, stipulated in the Put Notice of the Company, then the dollar amount of the Put shall be reduced by 10% for each such day. The Company may stipulate a Floor Price below which, no shares of common stock may be sold by Southridge, however, the Floor price shall not be lower than the lowest daily volume weighted average price of the common stock during the ten trading days preceding the date of the Put Notice.

The Company also entered into a registration rights agreement (the "Registration Rights Agreement") with Southridge. Pursuant to the terms of the Registration Rights Agreement, the Company filed a registration statement with the SEC, which was declared effective on August 4, 2015, covering 205,000,000 shares of common stock underlying the 2015 EP Agreement.

In August 2015, the Company delivered 13,900,000 registered shares of its common stock to Southridge in accordance with the requirements for issuing a Put Notice under the 2015 EP Agreement.

Issuance of Convertible Promissory Note

In July 2015, the Company issued a \$63,000 convertible promissory note which bears interest at the rate of 8% per annum and matures in April 2016, if not converted prior thereto. The Company received net proceeds of \$60,000 after transaction costs. The note may be prepaid during the first six months the note is outstanding by paying a prepayment penalty equal to 30% during the first 60 days, increasing in 5% increments each month to a maximum of 50%. Commencing 180 days after issuance, the note is convertible at any time, in whole, or in part, at the option of the holder at a conversion rate equal to 61% of the average of the three lowest closing bid prices during the 10-day trading period prior to the date of conversion. In connection with the issuance of this convertible note, the Company has reserved 135,000,000 shares of its common stock in anticipation of the note being converted.

Conversion and Repayment of Convertible Promissory Notes

In July and August 2015, in two transactions, \$54,000 principal amount of convertible promissory notes, including accrued interest thereon were converted into 19,091,175 unregistered, restricted shares of the Company's common stock.

Issuance of Anti-dilution shares

In August 2015, the Company issued 124,240, 8,458 and 662 shares of Series B Convertible Preferred Stock to George J. Coates, Gregory G. Coates and Barry C. Kaye, respectively, representing anti-dilution shares related to newly issued shares of common stock. The estimated fair value of these shares was \$954,000, \$65,000 and \$5,000, respectively.

Issuance and Repayments of Promissory Notes to Related Parties

In July 2015, the Company repaid 17% promissory notes due to George J. Coates and Bernadette Coates amounting \$20,000 and \$5,000, respectively, including interest thereon of \$3,000 to Mr. Coates.

Deferred Compensation

As of August 12, 2015, George J. Coates, Barry C. Kaye and Bernadette Coates agreed to additional deferral of their compensation amounting to \$29,000, \$14,000 and \$8,000, respectively, and in July 2015, Mr. Kaye was paid \$15,000, bringing their total deferred compensation to \$635,000, \$101,000 and \$166,000, respectively.

Extension of Mortgage Loan

On July 22, 2015, the Company was notified that the mortgage loan on its headquarters and research and development facility has been extended by the lender for an additional three years until July 1, 2018, on the same terms and conditions.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

Cautionary Notice Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q (this "Report") contains "forward-looking statements" within the meaning of the Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act of 1934, as amended. Forward-looking statements discuss matters that are not historical facts. Because they discuss future events or conditions, forward-looking statements may include words such as "anticipate," "believe," "estimate," "intend," "could," "should," "would," "may," "seek," "plan," "might," "will," "expect," "predict," "project," "forecast," "potential," "continue" negatives thereof or similar expressions. These forward-looking statements are found at various places throughout this Report and include information concerning possible or assumed future results of our operations; business strategies; future cash flows; financing plans; plans and objectives of management; any other statements regarding future operations, future cash needs, business plans and future financial results, and any other statements that are not historical facts.

From time to time, forward-looking statements also are included in our other periodic reports on Forms 10-K and 8-K, in our press releases, in our presentations, on our website and in other materials released to the public. Any or all of the forward-looking statements included in this Report and in any other reports or public statements made by us are not guarantees of future performance and may turn out to be inaccurate. These forward-looking statements represent our intentions, plans, expectations, assumptions and beliefs about future events and are subject to risks, uncertainties and other factors. Many of those factors are outside of our control and could cause actual results to differ materially from the results expressed or implied by those forward-looking statements. In light of these risks, uncertainties and assumptions, the events described in the forward-looking statements might not occur or might occur to a different extent or at a different time than we have described. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this Report. All subsequent written and oral forward-looking statements concerning other matters addressed in this Report and attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this Report.

For a discussion of factors that we believe could cause our actual results to differ materially from expected and historical results see "Item 1A - Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2014 filed with the Securities and Exchange Commission.

Background

We have completed development of the Coates spherical rotary valve engine technology. This technology has been successfully applied to natural gas fueled industrial electric power CSRV® generator engines ("Gen Sets), automobile engines, residential generators and high performance racing car engines. We have also designed and retrofitted the CSRV® system technology into a diesel engine which is suitable for and can be applied to heavy trucks. In February 2015, we granted a US\$100 million non-exclusive distribution sublicense with a China-based sales and distribution company that covers distribution in the territory of the Western Hemisphere. We also undertook to procure parts and components to commence limited production of our Gen Sets. We began receiving certain parts and components in the first quarter, some of which require additional manufacturing processes by other vendors and expect to continue to receive and process additional parts and components on an ongoing basis.

In the fourth quarter of 2011, we identified cracks on the lower engine heads that resulted from a manufacturing defect by one of our suppliers. Based on our testing of the Gen Sets to confirm our resolution of this problem, we believe we have determined the cause of this cracked head condition. As discussed above, we are currently procuring new production parts and components and are in the process of manufacturing a limited number of Gen Sets intended for installation in end-user customer oil fields and other applications.

Independent testing on internal combustion engines incorporating the CSRV® system technology indicated the following advantages would be derived from this technology:

- · Better fuel efficiency
- · Reduced harmful emissions

Based on more than ten years of operating a Mercedes 300 with an SE 280 engine retrofitted with the CSRV® system technology, the following advantages were demonstrated:

- Longer intervals between engine servicing, and
- Longer engine life than conventional internal combustion engines.

We continue to be engaged in new research and development activities from time-to-time in connection with applying this technology to other commercially feasible internal combustion engine applications and intend to manufacture engines and/or license the CSRV® system technology to third party Original Equipment Manufacturers ("OEM's") for multiple other applications and uses.

Hydrogen Reactor Technology Owned by George J. Coates

George J. Coates has developed a hydrogen reactor, which rearranges H₂O water molecules into HOH molecules also known as Hydroxy-Gas. The Hydroxy-Gas produced by the hydrogen reactor is then harvested for use as a type of fuel. Mr. Coates has agreed to continue further development of this technology to enable the harvested Hydroxy-Gas to be utilized as the fuel source to power our patented CSRV® engines. This technology has been successfully applied to a small CSRV® engine which is solely powered by Hydroxy gas produced by the reactor from water. However, at this time, the Hydrogen Reactor technology development has been temporarily deferred to enable the Company to focus on producing a limited number of Gen Sets. Mr. Coates intends to continue with research and development of the next application of this technology in an attempt to power larger, industrial engines. If successful, the Hydrogen Reactor technology will only require a ready supply of water and would be suitable for stationary engines and generators. Conventional internal combustion engines employing poppet valve assemblies require lubrication and would experience excessive heat and friction if powered with Hydroxy-Gas. This, in turn, would cause the engines to burn out in a rather short period of time. The materials and components of the CSRV® engines do not require such lubrication and their design enables them to operate relatively trouble-free on Hydroxy-Gas as the engine fuel. There can be no assurance that this technology can be developed successfully, or that if developed, it will be feasible to penetrate the internal combustion engine market with this technology. Application for patent protection of this technology will be filed upon completion of the research and development. Although at this time no arrangements have been made between the Company and George J. Coates, owner of the technology, regarding licensing of the hydrogen reactor, Mr. Coates has provided his commitment to license this technology to the Company once the related patent protection is in place. Accordingly, the Company does not currently have any rights to manufacture, use, sell and distribute the Hydrogen Reactor technology, should it become commercially feasible to manufacture and distribute products powered by the Hydroxy-Gas fuel. The Company has been and continues to be responsible for all costs incurred related to the development of this technology.

Plan of Operation

Manufacturing, Sales and Distribution

We have completed development of the CSRV® system technology-based generator engine and are currently engaged in producing a limited number of Gen Sets, which will incorporate our solution for the cracked heads, as a prelude to entering into the production phase of our operations. We will need to raise sufficient new working capital for production. We intend to sell the initial Gen Sets to Almont Energy, Inc., ("Almont") to be field tested. Almont, our sublicensee, is a privately held, independent third party entity based in Alberta, Calgary, Canada.

We intend to take advantage of the fact that essentially all the parts and components of the CSRV® generator engine may be readily sourced and acquired from U.S. based suppliers and subcontractors, and, accordingly, expect to manufacture Gen Sets by developing assembly lines within owned manufacturing facilities. The initial limited production will enable us to prove our concept for the CSRV® system technology and we expect this will dovetail with the existing substantial demand in the marketplace. We plan to address this demand by establishing large scale manufacturing operations in the United States. Transitioning to large scale manufacturing is expected to require a substantial increase in our work force, securing additional manufacturing capacity and substantial capital expenditures.

Our ability to establish such manufacturing operations, recruit plant workers, finance initial manufacturing inventories and fund capital expenditures is highly dependent on our ability to successfully raise substantial new working capital in an amount and at a pace which matches our business plans. Potential sources of such new working capital include (i) sales of our equity and/or debt securities under our equity purchase agreement with Southridge, issuance of promissory notes to related parties and issuance of convertible notes, (ii) pursuing and entering into additional sublicensing agreements with Original Equipment Manufacturers ("OEM's") and/or distributors, and (iii) positive working capital generated from sales of our CSRV® products to Almont and others once we raise sufficient new working capital and commence production. Although we have been successful in raising sufficient working capital to continue our ongoing operations, we have encountered very challenging credit and equity investment markets, and have not been able to raise sufficient new working capital to enable us to commence production of our CSRV® products. There can be no assurance that we will be successful in raising adequate new working capital or even any new working capital to carry out our business plans. The current economic environment, which is characterized by tight credit markets, investor uncertainty about how to safely invest funds and low investor confidence, has introduced additional risk and difficulty to our challenge to secure such additional working capital.

Sublicensing

We plan to sublicense the CSRV® system technology to multiple OEM's in order to take advantage of third party manufacturers' existing production capacity and resources by signing OEM agreements.

In February 2015, we granted a non-exclusive distribution sublicense to Renown Power Development, Ltd., a China-based sales and distribution company ("Renown") covering the territory defined as the Western Hemisphere. Under this sublicense, Renown will be permitted to sell, lease and distribute CSRV® products. This sublicense provides for payment of licensing fees amounting to US\$100 million. We received an initial non-refundable deposit of \$500,000 to date. In addition, after Renown receives an aggregate of US\$10,000,000, it is required to pay us 25% of all funds it receives from any and all sources until the entire US\$100 million licensing fee is paid in full. In the event that Renown completes one or more capital raises aggregating US\$300 million or more, the remaining unpaid balance of the US\$100 million licensing fee shall become immediately due and payable.

As collateral for payment of the sublicensing fee, Coates Power, Ltd. an independent China-based manufacturing company that will produce CSRV® products in China ("Coates Power") and Renown are to place shares of their capital stock representing a 25% ownership interest into an escrow account for the benefit of Coates International, Ltd. These shares of stock will be released from escrow and revert back to Coates Power and Renown only after the US\$100 million sublicensing fee is paid in full. We do not have an ownership interest in Coates Power or Renown. Coates Power and Renown are controlled and managed by Mr. James Pang, our liaison agent in China.

Coates Power has agreed to initially source two completed Gen Sets from us. To date, we have received a deposit for these two Gen Sets of approximately US\$131,000. These Gen Sets are expected to be shipped in the near future.

Significant Estimates

The preparation of our financial statements in conformity with generally accepted accounting principles in the United States requires our management to make estimates and assumptions that affect the reported amount of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. These significant estimates include determining the fair value of convertible promissory notes containing embedded derivatives as a result of variable conversion rate provisions, determining a value for Series A Preferred Stock and Series B Convertible Preferred Stock issued in connection with anti-dilution provisions in place, assigning useful lives to the our property, plant and equipment, determining an appropriate amount to reserve for obsolete and slow moving inventory, providing a valuation allowance for deferred tax assets, assigning expected lives to and estimating the rate of forfeitures of stock options granted and selecting a volatility factor for the Company's stock options in order to estimate the fair value of the Company's stock options on the date of grant. Actual results could differ from those estimates.

Results of Operations for the Three Months Ended June 30, 2015 and 2014

Our principal business activities and efforts for the three months ended June 30, 2015 and 2014 were devoted to (i) commencing production of a limited number of CSRV[®] Industrial Generator Sets in the United States during 2015, including procurement of parts, (ii) undertaking efforts to raise additional working capital in order to fund ongoing operations and (iii) research and development of the Hydrogen Reactor Technology in 2014.

Although we incurred substantial net losses for the three months ended June 30, 2015 and 2014 of (\$4,024,135) and (\$2,353,518), respectively, it is important to consider that a substantial portion of these losses resulted from non-cash expenses required to be recorded for financial reporting purposes in accordance with GAAP. These net losses should be considered in view of the fact that actual cash used by operating activities amounting to (\$294,713) and (\$347,513) for the three months ended June 30, 2015 and 2014, respectively, was significantly less than these reported net losses.

Revenue

There were no sales for the three months ended June 30, 2015 and 2014.

Sublicensing fee revenue for the three months ended June 30, 2015 and 2014, amounted to \$4,800 and \$4,800, respectively. Sublicensing fees are being recognized by amortizing the license deposit of \$300,000 on the Canadian License over the approximate remaining life of the last CSRV[®] technology patent in force.

Expenses

Research and Development Expenses

Research and development activities for the three months ended June 30, 2015 and 2014, were primarily related to continuing refinement of production parts and components for CSRV® Industrial Gen Sets in the 2015 period and the Hydrogen Reactor Project in the 2014 period. Research and development expenses decreased by \$9,591 to \$95,833 in 2015 from \$105,424 in 2014. This net decrease is primarily due to a \$13,300 decrease in the amount of compensation and benefits allocated to research and development activities in the 2015 period.

Compensation and Benefits

Compensation and benefits increased to \$3,557,777 for the three months ended June 30, 2015 from \$1,527,224 for the three months ended June 30, 2014. This increase was primarily due to an increase in stock-based compensation of \$2,017,170, primarily consisting of issuances of Series B Convertible Preferred Stock to George J. Coates, Gregory G. Coates and Barry C. Kaye, for anti-dilution.

General and Administrative Expenses

General and administrative expenses decreased by \$47,602 to \$129,090 for the three months ended June 30, 2015 from \$176,692 for the three months ended June 30, 2014. This net decrease in 2015 was primarily related to decreases in legal and professional fees of (\$25,584), financing costs of (\$20,742), patent maintenance costs of (\$7,984), property taxes of (\$3,923), travel and entertainment of (\$3,741) and utilities of (\$3,125), offset by increases in investors relations costs of \$10,578 and printing costs of \$6,500 and a net increase in all other expenses of \$419.

Depreciation and Amortization

Depreciation and amortization expense decreased to \$11,797 for the three months ended June 30, 2015 from \$16,100 for the three months ended June 30, 2014.

Loss from Operations

A loss from operations of (\$3,789,697) was incurred for the three months ended June 30, 2015 compared with a loss from operations of (\$1,820,640) for the three months ended June 30, 2014.

Other Income (Expense)

Decrease (Increase) in Estimated Fair Value of Embedded Liabilities

The estimated fair value of embedded liabilities, which relates to outstanding convertible promissory notes, is remeasured at each balance sheet date. For the three months ended June 30, 2015 and 2014, other income (expense) was recorded to reflect the decrease (increase) in the fair value of embedded liabilities of \$27,863 and (\$289,563), respectively.

Loss on conversion of convertible notes

For the three months ended June 30, 2015 and 2014, the Company realized a loss on conversion of convertible notes of (\$133,566) and (\$25,089), respectively.

Interest Expense

Interest expense decreased to \$128,735 for the three months ended June 30, 2015 from \$218,226 in 2014, primarily to a lower level of outstanding convertible notes.

Deferred Taxes

For the three months ended June 30, 2015 and 2014, the change in deferred taxes was fully offset by a valuation allowance, resulting in a \$-0- net income tax provision.

Net Loss

For the three months ended June 30, 2015, we incurred a net loss of (\$4,024,135) or (\$0.01) per share, as compared with net loss of (\$2,353,518) or (\$0.01) per share for three months ended June 30, 2014. Included in the net losses for the three months ended June 30, 2015 and 2014 was \$2,438,702 and \$145,938, respectively, of non-cash expenses, net of non-cash revenues.

Results of Operations for the Six Months Ended June 30, 2015 and 2014

Our principal business activities and efforts for the six months ended June 30, 2015 and 2014 were devoted to (i) negotiating and granting a US \$100 Million non-exclusive distribution license with Renown Power Development, Ltd., a China-based company which was consummated in February 2015, (ii) in 2015, commencing production of a limited number of CSRV[®] Industrial Generator Sets in the United States, including procurement of parts, (iii) undertaking efforts to raise additional working capital in order to fund ongoing operations, and (iv) research and development of the Hydrogen Reactor Technology in 2014.

Although we incurred substantial net losses for the six months ended June 30, 2015 and 2014 of (\$6,838,904) and (\$2,864,737), respectively, it is important to consider that a substantial portion of these losses resulted from non-cash expenses required to be recorded for financial reporting purposes in accordance with GAAP. These net losses should be considered in view of the fact that actual cash used by operating activities amounting to (\$429,364) and (\$724,908) for the six months ended June 30, 2015 and 2014, respectively, was significantly less than these reported net losses. The differences between the reported net loss and actual cash used in our results of operations for the six months ended June 30, 2015 and 2014 are described in detail in the section "Liquidity and Capital Resources".

Revenue

There were no sales for the six months ended June 30, 2015 and 2014.

Sublicensing fee revenue for the six months ended June 30, 2015 and 2014, amounted to \$9,600 and \$9,600, respectively. Sublicensing fees are being recognized by amortizing the license deposit of \$300,000 on the Canadian License over the approximate remaining life of the last CSRV[®] technology patent in force.

Expenses

Research and Development Expenses

Research and development activities for the six months ended June 30, 2015 and 2014, were primarily related to continuing refinement of production parts and components for CSRV® Industrial Gen Sets in the 2015 period and the Hydrogen Reactor Project in the 2014 period. Research and development expenses decreased by \$29,850 to \$189,744 in 2015 from \$219,594 in 2014. This net decrease is due to a \$36,100 decrease in the amount of compensation and benefits allocated to research and development activities, partially offset by an increase in parts used for research and development of \$6,250 in 2015.

Compensation and Benefits

Compensation and benefits increased to \$5,786,012 for the six months ended June 30, 2015 from \$1,644,809 for the six months ended June 30, 2014. This increase was primarily due to an increase in stock-based compensation of \$4,106,505, primarily consisting of issuances of Series B Convertible Preferred Stock to George J. Coates, Gregory G. Coates and Barry C. Kaye, for anti-dilution.

General and Administrative Expenses

General and administrative expenses decreased by \$46,898 to \$277,294 for the six months ended June 30, 2015 from \$324,192 for the six months ended June 30, 2014. This net decrease in 2015 was primarily related to decreases in legal and professional fees of (\$27,715), financing costs of (\$18,146), utilities of (\$8,854), property taxes of (\$8,038), travel and entertainment of (\$3,775), technology costs of (\$3,229) and postage of (\$2,705), partially offset by increases in investors relations costs of \$13,312, patent maintenance costs of \$10,170, building expenses of \$2,043 and a net increase in all other expenses of \$39.

In order to preserve our working capital, George J. Coates, Barry C. Kaye and Bernadette Coates have voluntarily agreed to defer payment of a portion of their compensation for certain periods in 2013, 2014 and 2015, which as of August 11, 2015, amounted to approximately \$635,000, \$101,000 and \$166,000, respectively. This deferred compensation is intended to be paid when we are successful in our efforts to raise sufficient new working capital.

Depreciation and Amortization

Depreciation and amortization expense decreased to \$27,759 for the six months ended June 30, 2015 from \$32,721 for the six months ended June 30, 2014.

Loss from Operations

A loss from operations of (\$6,271,209) was incurred for the six months ended June 30, 2015 compared with a loss from operations of (\$2,211,716) for the six months ended June 30, 2014.

Other Income (Expense)

Decrease (Increase) in Estimated Fair Value of Embedded Liabilities

The estimated fair value of embedded liabilities, which relates to outstanding convertible promissory notes, is remeasured at each balance sheet date. For the six months ended June 30, 2015 and 2014, other income (expense) was recorded to reflect the decrease (increase) in the fair value of embedded liabilities of \$71,895 and (\$172,547), respectively.

Loss on conversion of convertible notes

For the six months ended June 30, 2015 and 2014, the Company realized a loss on conversion of convertible notes of (\$238,070) and (\$61,713), respectively.

Interest Expense

Interest expense decreased to \$401,520 for the six months ended June 30, 2015 from \$418,761 in 2014. Interest expense in 2015 consisted of non-cash interest related to convertible promissory notes of \$295,471, mortgage loan interest of \$44,819, interest on promissory notes to related parties of \$39,971, interest expense related to the sale/leaseback of equipment of \$18,989 and net other interest of \$2,270. Interest expense in 2014 consisted of non-cash interest related to convertible promissory notes of \$267,566, interest on promissory notes to related parties of \$66,935, mortgage loan interest of \$56,422, interest expense related to the sale/leaseback of equipment of \$27,541 and other interest of \$297.

Deferred Taxes

For the six months ended June 30, 2015 and 2014, the change in deferred taxes was fully offset by a valuation allowance, resulting in a \$-0- net income tax provision.

Net Loss

For the six months ended June 30, 2015, we incurred a net loss of (\$6,838,904) or (\$0.01) per share, as compared with net loss of (\$2,864,737) or (\$0.01) per share for six months ended June 30, 2014. Included in the net losses for the six months ended June 30, 2015 and 2014 was \$6,126,580 and \$2,063,932, respectively, of non-cash expenses.

Liquidity and Capital Resources

Our cash position at June 30, 2015 was \$107,831, a decrease of \$155,695 from the cash position of \$263,526 at December 31, 2014. We had negative working capital of (\$5,205,634) at June 30, 2015 which represents an improvement in our working capital of \$2,090,488 compared to the (\$7,296,122) of negative working capital at December 31, 2014. Our current liabilities of \$5,462,396 at June 30, 2015, decreased by \$2,189,400 from \$7,651,796 at December 31, 2014. This net decrease primarily resulted from (i) the reclassification of the \$1,358,284 non-current portion of mortgage loan which was extended for three years, to non-current liabilities, (ii) the reclassification of the \$456,775 non-current portion of the deposit from Renown, upon becoming non-refundable, to non-current liabilities, (iii) a \$391,328 decrease in the carrying amount of convertible notes, net of unamortized discount, (iv) a \$71,895 net decrease in the derivative liability related to convertible promissory notes and (v) a \$64,000 decrease in promissory notes payable to related parties, partially offset by (vi) a \$131,471 increase in a deposit on an order and (vii) a \$61,702 increase in accounts payable and accrued liabilities.

Operating activities utilized cash of (\$429,364) for the six months ended June 30, 2015, a decrease of \$295,544 from the cash utilized for operating activities of (\$724,908) for the six months ended June 30, 2014. Cash utilized by operating activities in the six months ended June 30, 2015 resulted primarily from (i) a cash basis net loss of (\$712,325), after adding back non-cash stock-based compensation expense of \$5,632,931, non-cash interest and amortization of discount on convertible notes and finance lease obligation of \$299,714, a non-cash loss on conversion of convertible notes of \$238,070 and depreciation and amortization of \$27,759, partially offset by, a non-cash decrease in embedded derivative liabilities related to convertible notes of (\$71,895); and (ii) an increase in inventory of \$98,309, a decrease in deferred offering costs and other assets of \$41,526, an increase of \$49,652 in accounts payable and accrued liabilities, an increase in deposit on order of \$131,471 and an increase in deferred compensation payable of \$158,619.

Cash used in investing activities of \$22,358 for the six months ended June 30, 2015, consisted of outlays for new patterns for Gen Set production parts.

Cash provided by financing activities for the six months ended June 30, 2015, amounted to \$271,027. This was comprised of proceeds from issuances of convertible promissory notes aggregating \$252,500, issuances of common stock under an equity purchase agreement of \$207,261 and proceeds from issuances of promissory notes to related parties amounting to \$60,000, partially offset by repayments of promissory notes held by related parties of (\$124,000), cash repayment of convertible promissory notes of (\$52,750), principal repayments of (\$30,000) on a mortgage loan payable and payments of a finance lease obligation amounting to (\$16,984).

Going Concern

We have incurred net recurring losses since inception, amounting to (\$53,606,083) as of June 30, 2015 and had a stockholders' deficiency of (\$5,124,900). We will need to obtain additional working capital in order to continue to cover our ongoing cash expenses.

These factors raise substantial doubt about our ability to continue as a going concern. In addition, the current economic environment, which is characterized by tight credit markets, investor uncertainty about how to safely invest funds and low investor confidence, has introduced additional risk and difficulty to our challenge to secure needed additional working capital. Our Independent Registered Public Accountants have stated in their Auditor's Report dated March 30, 2015, with respect to our financial statements as of and for the year ended December 31, 2014, that these circumstances raise substantial doubt about our ability to continue as a going concern.

During 2015, we restricted variable costs to only those expenses that are necessary to perform activities related to efforts to negotiate sublicenses for distribution of our $CSRV^{\textcircled{@}}$ products, raising working capital to enable us to commence production of our $CSRV^{\textcircled{@}}$ system technology products, research and development and general administrative costs in support of such activities.

Our financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

Sources of working capital and new funding being pursued by us include (i) sales of common stock and warrants, (ii) issuances of promissory notes and convertible promissory notes, (iii) new equity investment and/or up front licensing fees from prospective new sublicensees and (iv) manufacturing and sales of CSRV[®] Units. There can be no assurance that we will be successful in securing any of these sources of additional funding. In this event, we may be required to substantially or completely curtail our operations, which could have a material adverse effect on our operations and financial condition.

At June 30, 2015, current liabilities amounted to \$5,462,396, primarily comprised of promissory notes due to related parties aggregating \$1,501,505, \$1,344,336 of legal and professional fees, deferred compensation of \$1,078,524, an embedded derivative liability related to our convertible promissory notes of \$403,800, accrued interest expense of \$376,108, accrued general and administrative expenses of \$209,176, deposits of \$150,595, accrued research and development expenses of \$114,859, \$109,577 of convertible promissory notes, net of unamortized discount, the current portion of license deposits of \$60,725, the current portion of a mortgage loan amounting to \$60,000 and the current portion of a finance lease obligation of \$53,191.

Contractual Obligations and Commitments

The following table summarizes our contractual obligations and commitments at June 30, 2015:

	Total		2015		2016		2017		2018	
Promissory notes to related parties	\$	1,501,505	\$	1,501,505	\$	-	\$	-	\$	-
Mortgage loan payable		1,418,284		30,000		60,000		60,000		1,268,284
Deferred compensation		1,078,524		1,078,524		-		-		-
Convertible promissory notes		234,542		79,125		155,417		-		-
Finance lease obligation		61,176		61,176		-		-		-
Total	\$	4,294,031	\$	2,750,330	\$	215,417	\$	60,000	\$	1,268,284

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements.

Critical Accounting Policies

The Company's significant accounting policies are presented in the Company's notes to financial statements for the period ended June 30, 2015, which are contained in this filing, the Company's 2015 Quarterly Report on Form 10-Q for the first quarter of 2015 and notes to financial statements for the year ended December 31, 2014 which are contained in the Company's 2014 Annual Report on Form 10-K. The significant accounting policies that are most critical and aid in fully understanding and evaluating the reported financial results include the following:

The Company prepares its financial statements in conformity with generally accepted accounting principles in the United States of America. These principals require management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management believes that these estimates are reasonable and have been discussed with the Board of Directors; however, actual results could differ from those estimates

Long-lived assets such as property, equipment and identifiable intangibles are reviewed for impairment whenever facts and circumstances indicate that the carrying value may not be recoverable. When required, impairment losses on assets to be held and used are recognized based on the fair value of the asset. The fair value is determined based on estimates of future cash flows, market value of similar assets, if available, or independent appraisals, if required. If the carrying amount of the long-lived asset is not recoverable from its undiscounted cash flows, an impairment loss is recognized for the difference between the carrying amount and fair value of the asset. When fair values are not available, the Company estimates fair value using the expected future cash flows discounted at a rate commensurate with the risk associated with the recovery of the assets. We did not recognize any impairment losses for any periods presented.

Other significant estimates include determining the fair value of convertible promissory notes containing embedded derivatives and variable conversion rates, determining a value for Series A Preferred Stock and Series B Convertible Preferred Stock issued, assigning useful lives to the Company's property, plant and equipment, determining an appropriate amount to reserve for obsolete and slow moving inventory, estimating a valuation allowance for deferred tax assets, assigning expected lives to, and estimating the rate of forfeitures of, stock options granted and selecting a trading price volatility factor for the Company's common stock in order to estimate the fair value of the Company's stock options on the date of grant or other appropriate measurement date. Actual results could differ from those estimates.

New Accounting Pronouncements

In July 2015, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update No. 2014-15, "Inventory – Simplifying the Measurement of Inventory (Topic 330)". This update requires that inventory value be measured at the lower of cost or net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. Currently, generally accepted accounting principles require that inventory be valued at the lower of cost or market price to replace the inventory. This update is to become effective for annual and interim financial statements for fiscal years ending after December 15, 2016. Earlier application is permitted. This update is required to be applied prospectively. The Company is currently evaluating the impact of this update; however, at this time it does not expect it will have a material effect on its financial statements.

In August 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update No. 2014-15, "Presentation of Financial Statements - Going Concern (Subtopic 205-40)", which was issued in order to provide guidance about management's responsibility to evaluate whether there is substantial doubt about an entity's ability to continue as a going concern and to provide related financial statement disclosures. It requires that management evaluate whether there are conditions or events, when considered in the aggregate, that raise substantial doubt about the entity's ability to continue as a going concern within one year after the date of both the annual and interim financial statements ("Going Concern Doubt"). The evaluation should be based on relevant conditions and events that are known and reasonably knowable at the date of the financial statements. When such evaluation determines that Going Concern Doubt does exist, then management is required to consider whether or not it is probable that its plans to mitigate the Going Concern Doubt can be effective and timely to address the Going Concern Doubt. This update provides disclosure requirements in the notes to financial statements both when such doubt is probable of being mitigated and when such doubt is not probable of being mitigated by management's plans. This update is to become effective for annual and interim financial statements for fiscal years ending after December 15, 2016. As permitted thereunder, we have elected to implement this update early and it has been applied in the financial statements for the six months ended June 30, 2015, included in this Form 10-Q. Early adoption did not have a material effect on our financial position or results of operations.

In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update No. 2014-09, "Revenue from Contracts with Customers (Topic 606)", which amended the existing accounting standards for revenue recognition. This update is based on the principle that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company is required to adopt this updated standard in the first quarter of fiscal 2018. Early adoption is not permitted. The amendments may be applied retrospectively to each prior period presented or retrospectively with the cumulative effect recognized as of the date of initial application. The Company is currently evaluating the impact of this update and the transition alternatives; however, at this time it does not expect it will have a material effect on its financial statements.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

We are not required to provide the information under this item as we are a smaller reporting company.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls

Pursuant to Rule 13a-15(b) under the Securities Exchange Act of 1934 (the "Exchange Act"), we carried out an evaluation, with the participation of our management, including our Chief Executive Officer ("CEO") and Chief Financial Officer ("CFO") (our principal financial and accounting officer), of the effectiveness of our disclosure controls and procedures (as defined under Rule 13a-15(e) under the Exchange Act) as of the end of the period covered by this report. Based upon that evaluation, our CEO and CFO concluded that our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to our management, including our CEO and CFO, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There have been no changes in our internal control over financial reporting that occurred during the last fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

We are currently not involved in any litigation that we believe could have a materially adverse effect on our financial condition or results of operations. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of our company or any of our subsidiaries, threatened against or affecting our company, our common stock, any of our subsidiaries or of our company's or our company's subsidiaries' officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect.

Item 1A. Risk Factors

We believe there are no changes that constitute material changes from the risk factors previously disclosed in the Company's 2014 Annual Report filed on Form 10-K.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

The following issuances of securities since December 31, 2014 were exempt from registration pursuant to Section 4(2), and Regulation D promulgated under the Securities Act. We made this determination based on the representations of the Investors which included, in pertinent part, that such Investors were "accredited investors" within the meaning of Rule 501 of Regulation D promulgated under the Securities Act, and that such Investors were acquiring our common stock for investment purposes for their own respective accounts and not as nominees or agents, and not with a view to the resale or distribution thereof, and that the Investors understood that the shares of our common stock may not be sold or otherwise disposed of without registration under the Securities Act or an applicable exemption therefrom.

In a series of transactions, we issued five convertible promissory notes to various investors and received net proceeds of \$252,500. The nominal interest rate on these notes ranged from 8% to 12%. These notes are convertible into unregistered shares of our common stock at any time beginning six months after issuance. These convertible notes provided for conversion rates at discounts from the trading price of our common stock over a defined number of trading days leading up to the date of conversion (the "Market Price"). The discounts ranged from 30% to 40% of the Market Price.

In a series of transactions, an aggregate of \$709,686 principal amount of convertible promissory notes, including accrued interest was converted by the holders into 434,908,904 unregistered shares of our common stock.

Net proceeds from the above transactions were used for general working capital purposes.

Item 3. Defaults upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not Applicable.

Item 5. Other Information

None.

Item 6. Exhibits

Exhibit Number	Description
31.1	Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1	Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2	Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS	XBRL Instance Document
101.SCH	XBRL Taxonomy Schema
101.CAL	XBRL Taxonomy Calculation Linkbase
101.DEF	XBRL Taxonomy Definition Linkbase
101.LAB	XBRL Taxonomy Label Linkbase
101.PRE	XBRL Taxonomy Presentation Linkbase
101.DE	XBRI. Taxonomy Extension Definition Linkbase Document

In accordance with SEC Release 33-8238, Exhibit 32.1 and 32.2 are being furnished and not filed.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

COATES INTERNATIONAL, LTD.

/s/ George J. Coates

Date: August 12, 2015

Date: August 12, 2015

George J. Coates Duly Authorized Officer, President and

Chief Executive Officer (Principal Executive Officer)

/s/ Barry C. Kaye

Barry C. Kaye
Duly Authorized Officer, Treasurer and
Chief Financial Officer
(Principal Financial Officer)

- 45 -

CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

- I, George J. Coates, certify that:
- 1. I have reviewed this Quarterly Report on Form 10-Q of Coates International, Ltd. (the "registrant");
- 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
- 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
- 4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
- a) Designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
- b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
- c) Evaluated the effectiveness of the registrant's disclosure controls and procedures; and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and
- d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
- 5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
- a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
- b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 12, 2015

/s/ George J. Coates

George J. Coates President and Chief Executive Officer (Principal Executive Officer)

CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

- I, Barry C. Kaye, certify that:
- 1. I have reviewed this Quarterly Report on Form 10-Q of Coates International, Ltd. (the "registrant");
- 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
- 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
- 4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
- a) Designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
- b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
- c) Evaluated the effectiveness of the registrant's disclosure controls and procedures; and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and
- d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
- 5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
- a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
- b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 12, 2015 /s/ Barry C. Kaye

Barry C. Kaye Chief Financial Officer (Principal Financial Officer)

CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (18 U.S.C. SECTION 1350)

In connection with the Quarterly Report of Coates International, Ltd. (the "Company") on Form 10-Q for the period ended June 30, 2015 (the "Report"), I, George J. Coates, Chief Executive Officer of the Company, hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002, that:

- 1. The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and
- 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 12, 2015 /s/ George J. Coates

George J. Coates President and Chief Executive Officer (Principal Executive Officer)

CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (18 U.S.C. SECTION 1350)

In connection with the Quarterly Report of Coates International, Ltd. (the "Company") on Form 10-Q for the period ended June 30, 2015 (the "Report"), I, Barry C. Kaye, Chief Financial Officer of the Company, hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002, that:

- 1. The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and
- 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 12, 2015 /s/ Barry C. Kaye

Barry C. Kaye Treasurer and Chief Financial Officer (Principal Financial Officer)